Ecaterina E Dumbrava, M.D.

Peer-Reviewed Articles

1. Tan HN, Stephen B, Mirallas O, Derbala MH, Salih I, Castillo L, Yang Y, Le H, Kang L, Lin H, Lim J, Dumbrava EE, Yap TA, Rodon J, Piha-Paul SA, Fu S, Champiat S, Akhave N, Ferrarotto R, Hong DS, Meric-Bernstam F, Johnson F, Naing A. Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer. JAMA Netw Open 9(7):e2623522, 2026. e-Pub 2026. PMID: 42461627.
2. Tan HN, Le H, Frej KBH, Kang L, Champiat S, Meric-Bernstam F, Fossella F, Naing A, Sharon E, Altan M, Dumbrava EE. Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors. NPJ Precis Oncol, 2026. e-Pub 2026. PMID: 42286316.
3. Nevins Selvadurai, P, Tan, HN, Song, J, Stephen, B, Kang, L, Mirallas Vinas, O, Derbala, M, Salih, I, Castillo, L, Yang, Y, Le, H, Dumbrava, EE, Yap, TA, Rodon Ahnert, J, Piha-Paul, SA, Fu, S, Champiat, S, Hong, DS, Meric-Bernstam, F, Naing, A. Prognostic value of serum tumor markers in phase I immunotherapy trials. Journal of Clinical Oncology 44:e14534–e14534, 2026. e-Pub 2026.
4. Dumbrava EE, Olson D, Gouda MA, George MA, Saibil SD, Apostolopoulou M, Bishop M, Gavriliuc MN, Kennon AM, Weiss JA, Ayers C, Moss K, Helsen CW, Rill D, Bader AG, Adib D, Schlechter BL. Autologous T Cell Antigen Coupler Targeting HER2 (TAC01-HER2) in Advanced or Metastatic Solid Tumors. Ann Oncol. e-Pub 2026. PMID: 42177028.
5. Nevins Selvadurai, P, Tan, HN, Song, J, Stephen, B, Kang, L, Mirallas Vinas, O, Derbala, M, Salih, I, Castillo, L, Yang, Y, Le, H, Dumbrava, EE, Yap, TA, Rodon Ahnert, J, Piha-Paul, SA, Fu, S, Champiat, S, Hong, DS, Meric-Bernstam, F, Naing, A. Prognostic value of serum tumor markers in phase I immunotherapy trials. ASCO Annual Meeting 44:e14534–e14534, 2026. e-Pub 2026.
6. Venturini J, Baysal MA, Chakraborty A, Yap TA, Fu S, Hong DS, Piha-Paul SA, Naing A, Ahnert JR, Dumbrava EE, Beck J, Liu Y, Kahle M, Vining DJ, Meric-Bernstam F, Tsimberidou AM. Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study. NPJ Precis Oncol 10(1), 2026. e-Pub 2026. PMID: 41963611.
7. Torrado Martin C, Andersen C, Kang L, Brink AL, Adesoye T, Le H, Patterson CJ, Poullard, A, Osburn JA, Tan HN, Gouda M, Charles S, Urschel G, Tang T, Hong DS, Champiat S, Naing A, Tsimberidou AM, Dumbrava EE, Piha-Paul SA, Rodon Ahnert J, Yap TA, Pohlmann PR, Meric-Bernstam F, Fu S. Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity. Oncologist 31(4), 2026. e-Pub 2026. PMID: 41830429.
8. Uzunparmak B, Su F, Johnson A, Shaw KRM, Kong EK, Korkut A, Braganca Xavier C, Yuan Y, Fowler NH, Paradiso F, Kontselidze L, Butusova A, Bagaev A, Dumbrava EE, Rodon J, Hong DS, Yap TA, Fu S, Naing A, Piha-Paul SA, Ferrarotto R, Bryan J, Kulkarni S, Patel KP, Meric-Bernstam F. Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors. Cancer Discov, 2026. e-Pub 2026. PMID: 41885383.
9. Johnson A, Shen Y, Zheng X, Su F, Zeng J, Uzunparmak B, Breuer E, Holla V, Kahle M, Kim S, Vu T, Mills Shaw KR, Dumbrava, EE, Yap TA, Rodon Ahnert J, Routbort MJ, Patel KP, Kulkarni S, Hansel DE, Bryan J, Korkut A, Chen K, Meric-Bernstam F. The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology. Nature Reviews Clinical Oncology 23(3):213-229, 2026. e-Pub 2026. PMID: 41492079.
10. Dumbrava EE, Shapiro GI, Parikh AR, Johnson M, Tolcher AW, Thompson JA, El-Khoueiry AB, Vandross A, Kummar S, Shepard D, LeDuke K, Sheehan L, Alland L, Haque A, Jalota D, Fellous M, Schram AM. Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors. N Engl J Med 394(9):872-883, 2026. e-Pub 2026. PMID: 41740031.
11. Schmidt ST, Baysal M, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon Ahnert J, Yap TA, Dumbrava EE, Beck J, Meric-Bernstam F, Tsimberidou AM. Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology. Signal Transduct Target Ther 11(1):68, 2026. e-Pub 2026. PMID: 41730847.
12. Dumbrava E, Minchom A, Henry J, Johnson M, Sommerhalder D, Merchan J, Heist R, Cabanas EG, Cotreau M, Goenaga AL, Burzyn D, Makris L, Culm K, Abbadessa G. MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors. Future Oncol 22(3):305-312, 2026. e-Pub 2026. PMID: 41495607.
13. Beckham TH, Dudzinski SO, Rooney MK, Faraj CA, Pasli M, Perni S, Tom M, Ghia A, Yeboa DN, McAleer MF, Swanson T, McGovern S, Wang C, Chung C, De B, Jiang W, Kim BYS, Ferguson SD, Tawbi HA, Glitza I, Le X, Kaya D, Dumbrava EE, Briere T, Mackin D, Li J. Incorporating an NCCN-Based Systemic Therapy CNS Activity Score Into SRS Decision-Making for Patients With 5 or More Brain Metastases. J Natl Compr Canc Netw 24(2):34-40, 2026. e-Pub 2026. PMID: 41671425.
14. Schram AM, Park JJ, Italiano A, Kitano S, Guo Y, Li J, Bedard P, Van Marcke C, Ko R, Lunger L, Klotz DM, Hussain J, Maier D, Erzen D, Planchard D, Prenen H, Clay TD, Park JO, Kim HD, Hernando-Calvo A, Maruki Y, Ponz M, Dumbrava EE. Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors. Future Oncology 22(7):795-803, 2026. e-Pub 2026. PMID: 41777164.
15. Lim JU, Lin Y, Kang L, Le H, Tang T, Champiat S, Dumbrava EE, Le X, Naing A, Piha-Paul SA, Rodon Ahnert J, Tsimberidou AM, Yap TA, Fu S, Meric-Bernstam F, Hong DS. Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson. NPJ Precis Oncol 10(1), 2026. e-Pub 2026. PMID: 41530472.
16. Piha-Paul SA, Tseng C, Tran HT, Fu S, Dumbrava EE, Yap TA, Naing A, Lim J, Murphy MB, Ramirez DL, Soliman PT, Sood AK, Meric-Bernstam F. Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations. ESMO Open 10(12):105895, 2025. e-Pub 2025. PMID: 41223631.
17. Dumbrava, EE, Péloquin, S, Augustyniak, M, Vu, J, Kuo, EY, Lazure, P, Pasia, M, Rivera, S, Rodriguez, K, Subbiah, V, Murray, S. A performance and quality improvement intervention integrating molecular testing to support personalized cancer care in lung and thyroid cancers. ASCO Quality Care Symposium 21:260, 2025. e-Pub 2025.
18. George GC, Piha-Paul SA, Rodon Ahnert J, Dumbrava EE, Tsimberidou AM, Appleton G, Yap TA, Meric-Bernstam F, Hong DS. Dietary links with symptoms in early-phase immune checkpoint combinations trials. JCO Oncol Pract 21(11):341, 2025. e-Pub 2025.
19. Dumbrava EE, Stinchcombe TE, Gounder M, Cote GM, Hanna GJ, Sumrall B, Wise-Draper TM, Kanaan M, Duffy S, Sumey C, Cobb P, Forbes A, Beckmann AG, Schadt EE, Ku N, Tirunagaru VG, Singh K, Pei X, Xu F, Doebele RC, Chen C. Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53. Clin Cancer Res 31(20):4255-4264, 2025. e-Pub 2025. PMID: 40788172.
20. Braganca Xavier C, Andersen CR, Lim J, Slade JH, Bean SA, Kang L, Le H, Tsimberidou AM, Naing A, Hong DS, Dumbrava EE, Rodon Ahnert J, Pohlmann PR, Piha-Paul SA, Champiat S, Yap TA, Tang TY, Meric-Bernstam F, Fu S. Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit. Cancer Res Commun 5(9):1631-1641, 2025. e-Pub 2025. PMID: 40862547.
21. Schram AM, Takebe N, Chen A, Zhou Q, Iasonos A, Silber J, Reynolds M, Hussain S, Gavriliuc M, Smyth LM, Garrison D, Dumbrava EE. A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors. ESMO Open 10(9):105569, 2025. e-Pub 2025. PMID: 40939237.
22. Schram AM, Fellous M, LeDuke K, Schmid A, Dumbrava EE. PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation. Future Oncol 21(24):1-8, 2025. e-Pub 2025. PMID: 40932470.
23. Nelson BE, Janku F, Fu S, Dumbrava EE, Hong DS, Karp DD, Naing A, Rodon J, Tsimberidou AM, Murthy R, Sheth RA, Amaria RN, Conley AP, Damodaran S, Raghav KPS, Carapanceanu N, Singh MP, Carapanceanu V, Pezeshki A, Leontovich AA, Kreider BL, Tung D, Varterasian M, Khazaie K, Piha-Paul SA. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clin Cancer Res 31(18):3864-3875, 2025. e-Pub 2025. PMID: 40643985.
24. Gouda MA, Gonugunta A, Dumbrava EE, Yap TA, Rodon Ahnert J, Piha-Paul SA, Pohlmann PR, Damodaran S, Murthy RK, Valero V, Mouabbi JA, Tripathy D, Sahin AA, Chen H, Meric-Bernstam F. Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. Clin Cancer Res 31(7):1268-1274, 2025. e-Pub 2025. PMID: 39841861.
25. Michel L, Jimeno A, Sukari A, Beck JT, Chiu J, Ahern E, Hilton J, Even C, Zanetta S, Mekan S, Patel J, Wu T, Dumbrava EE. Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 31(5):832-838, 2025. e-Pub 2025. PMID: 39665770.
26. Piha-Paul SA, Tseng C, Tran HT, Naing A, Dumbrava EE, Karp DD, Rodon J, Yap TA, Raghav KP, Damodaran S, Le X, Soliman PT, Lim J, Meric-Bernstam F. Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations. ESMO Open 10(2):104136, 2025. e-Pub 2025. PMID: 39908697.
27. Stein MN, Dumbrava EE, Teply BA, Gergis U, Guiterrez ME, Reshef R, Subudhi SK, Jacquemont C, Senesac JH, Bayle JH, Scripture CD, Chatwal M, Bilen MA, Stadler WM, Becerra CR. PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer. Nature communications 15(1):10743, 2024. e-Pub 2024. PMID: 39737899.
28. Holla V, Kahle M, Kim SH, Ronaghy A, Yang RK, Patel KP, Routbort MJ, Overman MJ, Dumbrava EE, Mills Shaw KR, Karp DD, Meric-Bernstam F. Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types. JCO Precis Oncol 8:e2400419, 2024. e-Pub 2024. PMID: 39576951.
29. Tao DL, Nardo M, Leung CH, Lin HY, Kang L, Le H, Dumbrava EE, Hong DS. Obesity and Outcomes in Adoptive Cellular Therapy in Solid Tumors. JAMA Network Open 7(11), 2024. e-Pub 2024. PMID: 39585697.
30. Chang JY, Xu X, Shroff G, Comeaux NI, Li W, Rodon Ahnert J, Karp DD, Dumbrava EE, Verma V, Chen A, Welsh J, Hong DS. Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. J Immunother Cancer 12(10):e009975, 2024. e-Pub 2024. PMID: 39384194.
31. Mohamed YI, Lee SS, Demir T, Chamseddine SM, Hu ZI, Xiao L, Elsayes KM, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, Lapelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan MM, Amin HM, Kaseb A. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomarkers 41(1):83-91, 2024. e-Pub 2024. PMID: 39269823.
32. Tang C, Hartley G, Couillault CA, Yuan Y, Lin Y, Nicholas C, Srinivasamani A, Dai J, Dumbrava EEI, Fu S, Karp DD, Naing A, Piha-Paul SA, Rodon Ahnert J, Pant S, Subbiah V, Yap T, Tsimberidou AM, Guerrero PA, Dhebat S, Proia T, Curran M, Hong DS. Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer. BMJ Oncol 3(1), 2024. e-Pub 2024. PMID: 39886125.
33. Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P, Dumbrava EE. Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. J Clin Oncol 42(29):3421-3429, 2024. e-Pub 2024. PMID: 39083724.
34. Gouda MA, Shunyakova J, Naing A, Dumbrava E, Hong DS, Yuan Y, Yang P, Myers AL, Liang Y, Peng J, Karp DD, Tsimberidou AM, Rodon Ahnert J, Yap TA, Piha-Paul SA, Meric-Bernstam F, Fu S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ESMO Open 9(6), 2024. e-Pub 2024. PMID: 38914452.
35. Torrado Martin C, Brink A, Gouda M, Kang L, Osburn J, Patterson C, Charles S, Poullard A, Urschel G, Dumbrava EE, Karp D, Naing A, Piha-Paul S, Pohlmann P, Rodon Ahnert J, Tsimberidou A, Yap T, Hong D, Meric-Bernstam F, Fu S. Telehealth consultations and recruitment trends in clinical trials. ASCO Annual Meeting 42(Suppl 16):1635, 2024. e-Pub 2024.
36. DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov 14(5):828-845, 2024. e-Pub 2024. PMID: 38358339.
37. Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist 29(4):e514-e525, 2024. e-Pub 2024. PMID: 38297981.
38. Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EEI, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun 4(2):378-387, 2024. e-Pub 2024. PMID: 38126764.
39. Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 130(3):400-409, 2024. e-Pub 2024. PMID: 37864520.
40. Nowlen, CJ, Daniels, MS, Uzunparmak, B, Dumbrava, EE, Yuan, Y, Patel, KP, Rayes, N, Harkenrider, J, Wathoo, C, Veazie, J, Luna, KA, Wang, W, Horombe, C, Javle, M, Rodon Ahnert, J, Yap, TA, Arun, BK, Lu, KH, Meric-Bernstam, F. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. J Immunother Precis Oncol 7(1):7-17, 2024. e-Pub 2024. PMID: 38327755.
41. Chénard-Poirier, M, Almhanna, K, Lim, DT, El-Khoueiry, AB, Samol, J, Ryoo, BY, Yong Hong, J, Meng, R, Abbadessa, G, Masciari, S, Kefsi, A, Zhang, Y, Guillemin-Paveau, H, Pasquier, B, Lépine, L, Ileana Dumbrava, EE. Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors. Journal of Clinical Oncology 42(16):2579, 2024. e-Pub 2024.
42. Tao, DL, Nardo, M, Leung, CH, Lin, HY, Kang, L, Le, H, Ileana Dumbrava, EE, Hong, DS. The role of obesity on outcomes of adoptive cellular therapy in solid tumors. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
43. Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, Gorur A, Kirby B, Cimo AM, Kennon A, Ding Q, Urschel G, Yuan Y, Feng G, Rizvi Y, Hussain A, Zhu C, Kim P, Abbadessa G, Subbiah V, Yap TA, Rodon J, Piha-Paul SA, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol 34(11):1035-1046, 2023. e-Pub 2023. PMID: 37619847.
44. DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, Dumbrava EE, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res 29(21):4385-4398, 2023. e-Pub 2023. PMID: 37279095.
45. DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, Press MF, Piha-Paul SA, Dumbrava EE, Meric-Bernstam F. Discordance of HER2 Expression and/or Amplification on Repeat Testing. Mol Cancer Ther 22(8):976-984, 2023. e-Pub 2023. PMID: 37339271.
46. Chelariu-Raicu A, Piha-Paul SA, Chavez-MacGregor M, Johnson J, Sawaya R, McAleer MF, Nguyen A, Hartnett A, Tsimberidou AM, Meric-Bernstam F, Dumbrava EE. Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation. J Immunother Precis Oncol 6(3):158-161, 2023. e-Pub 2023. PMID: 37637237.
47. Zhao M, DiPeri TP, Raso MG, Zheng X, Rizvi YQ, Evans KW, Yang F, Akcakanat A, Roberto Estecio M, Tripathy D, Dumbrava EE, Damodaran S, Meric-Bernstam F. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. NPJ Breast Cancer 9(1):66, 2023. e-Pub 2023. PMID: 37567892.
48. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul SA, Moore JA, Yilmaz B, Ogbonna DC, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton D, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale PR, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer 129(14):2201-2213, 2023. e-Pub 2023. PMID: 37016732.
49. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol 41(9):1725-1734, 2023. e-Pub 2023. PMID: 36469840.
50. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol 6(1):10-18, 2023. e-Pub 2023. PMID: 36751659.
51. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
52. Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Gandhi L, Ghosh A, Hickman D, Gallacher PD, Wennborg A, Attar EC, Awad MM, Das S, Dumbrava EE. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open 7(5):100573, 2022. e-Pub 2022. PMID: 36084396.
53. Barber FD, Campbell E, Yamamura Y, Patterson CJ, Hartnett AC, Kinahan H, Miller VA, Brink AL, Poullard A, Urschel GE, Brantley A, Cepeda IG, Goswami P, Charles S, Philip S, Bresser S, Musekiwa-Adjei S, Perez N, Le H, Phillips P, Subbiah V, Meric-Bernstam F, Dumbrava EE. Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience. J Adv Pract Oncol 13(7):664-672, 2022. e-Pub 2022. PMID: 36199491.
54. Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep 12(1):14367, 2022. e-Pub 2022. PMID: 35999229.
55. Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep 12(1):8701, 2022. e-Pub 2022. PMID: 35610322.
56. Hong DS, Butler MO, Pachynski RK, Sullivan R, Kebriaei P, Boross-Harmer S, Ghobadi A, Frigault MJ, Dumbrava EE, Sauer A, Brophy F, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou DG, Wang R, Solis LM, Duose DY, Sanderson JP, Gerry AB, Marks D, Bai J, Norry E, Fracasso PM. Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol 12:818679, 2022. e-Pub 2022. PMID: 35372008.
57. Yap TA, Hamilton E, Bauer T, Dumbrava EE, Jeselsohn R, Enke A, Hurley S, Lin KK, Habeck J, Giordano H, Shapiro GI. Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients with Cancer With or Without Mutations in Homologous Recombination Repair Genes. JCO Precis Oncol 6:e2100456, 2022. e-Pub 2022. PMID: 35138920.
58. Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam F. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep 12(1):1248, 2022. e-Pub 2022. PMID: 35075200.
59. Dumbrava EE, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open 6(5):100230, 2021. e-Pub 2021. PMID: 34479035.
60. Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava El, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clin Cancer Res 27(11):3050-3060, 2021. e-Pub 2021. PMID: 33771853.
61. Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther 14:3037-3049, 2021. e-Pub 2021. PMID: 33994796.
62. Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Yang F, Bose PSC, Zheng X, Dumbrava EI, Aivado M, Meric-Bernstam F. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res 23(1):29, 2021. e-Pub 2021. PMID: 33663585.
63. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer 8(2):e000931, 2020. e-Pub 2020. PMID: 33097611.
64. Marcelo-Lewis KL, Moorthy S, Ileana-Dumbrava E. Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors. J Immunother Precis Oncol 3(3):121-127, 2020. e-Pub 2020. PMID: 35663256.
65. Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol 9:7, 2020. e-Pub 2020. PMID: 32337094.
66. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32188704.
67. Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Dumbrava EI, Janku F, Meric-Bernstam F. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. Oncotarget 11(No.11):961-981, 2020. e-Pub 2020. PMID: 32215185.
68. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw K, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications. JCO Precis Oncol 3:1-12, 2019. e-Pub 2019. PMID: 32923865.
69. Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Tapia C, Rizvi YQ, Dumbrava EI, Janku F, Meric-Bernstam F. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Oncotarget 10(49):5011-5019, 2019. e-Pub 2019. PMID: 31489111.
70. Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res 25(7):2033-2041, 2019. e-Pub 2019. PMID: 30442682.
71. Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 31517177.
72. Ileana Dumbrava E, Smith V, Alfattal R, El-Naggar AK, Penas-Prado M, Tsimberidou AM. Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment with Ipilimumab and Radiation Therapy. J Immunother 41(7):336-339, 2018. e-Pub 2018. PMID: 29787423.
73. Dumbrava EI, Ivan D, Subbiah V. Hypopigmented Skin Lesions After Immunotherapy. JAMA Oncol 4(8):1118-1119, 2018. e-Pub 2018. PMID: 29801033.
74. Ileana Dumbrava E, Meric-Bernstam F, Yap TA. Challenges with biomarkers in cancer drug discovery and development. Expert Opin Drug Discov 13(8):685-690, 2018. e-Pub 2018. PMID: 29792354.
75. Dumbrava EI, Alfattal R, Miller VA, Tsimberidou AM. Complete Response to a Fibroblast Growth Factor Receptor Inhibitor in a Patient With Head and Neck Squamous Cell Carcinoma Harboring FGF Amplifications. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 31123723.
76. Kurnit K, Dumbrava EEI, Litzenburger B, Khotskaya Y, Johnson A, Yap T, Rodon J, Zeng J, Shufean A, Bailey A, Sánchez N, Holla V, Mendelsohn J, Shaw K, Bernstam E, Mills G, Meric-Bernstam F. Precision oncology decision support: current approaches and strategies for the future. Clin Cancer Res 24(12):2719-2731, 2018. e-Pub 2018. PMID: 29420224.
77. Dumbrava EI, Meric-Bernstam F. Personalized cancer therapy- leveraging a knowledge base for clinical decision-making. Cold Spring Harb Mol Case Stud 4(2):1-9, 2018. e-Pub 2018. PMID: 29212833.
78. Ileana-Dumbrava E, Subbiah V. Autoimmune hypophysitis. Lancet Oncol 19(2):e123, 2018. e-Pub 2018. PMID: 29413466.
79. Daniels M, Wathoo C, Brusco L, Lu K, Shaw K, Dumbrava EEI, Arun B, Strong L, Litton J, Eterovic AK, Aytac U, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Active Disclosure of Secondary Germline Findings to Deceased Research Participants’ Personal Representatives: Process and Outcomes. JCO Precis Oncol 1, 2017. e-Pub 2017. PMID: 31552380.
80. Hollebecque A, Bahleda R, Faivre L, Adam J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, Gazzah A, Ileana E, Gharib M, Angevin E, Malekzadeh K, Massard C, Soria JC, Spano JP. Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. Eur J Cancer 81:81-89, 2017. e-Pub 2017. PMID: 28618305.
81. Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov 7(6):586-595, 2017. e-Pub 2017. PMID: 28365644.
82. Benajiba L, Michot JM, Baldini C, Faivre L, Varga A, Balheda R, Gazzah A, Ileana E, Postel-Vinay S, Massard C, de Botton S, Soria JC, Ribrag V. Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. Anticancer Drugs 28(5):540-545, 2017. e-Pub 2017. PMID: 28225458.
83. Jovelet C, Ileana E, Le Deley MC, Motté N, Rosellini S, Romero A, Lefebvre C, Pedrero M, Pata-Merci N, Droin N, Deloger M, Massard C, Hollebecque A, Ferté C, Boichard A, Postel-Vinay S, Ngo-Camus M, De Baere T, Vielh P, Scoazec JY, Vassal G, Eggermont A, André F, Soria JC, Lacroix L. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. Clin Cancer Res 22(12):2960-8, 2016. e-Pub 2016. PMID: 26758560.
84. Tacher V, Le Deley MC, Hollebecque A, Deschamps F, Vielh P, Hakime A, Ileana E, Abedi-Ardekani B, Charpy C, Massard C, Rosellini S, Gajda D, Celebic A, Ferté C, Ngo-Camus M, Gouissem S, Koubi-Pick V, Andre F, Vassal G, Deandreis D, Lacroix L, Soria JC, De Baère T. Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01). Eur J Cancer 59:79-89, 2016. e-Pub 2016. PMID: 27017289.
85. Postel-Vinay S, Boursin Y, Massard C, Hollebecque A, Ileana E, Chiron M, Jung J, Lee JS, Balogh Z, Adam J, Vielh P, Angevin E, Lacroix L, Soria JC. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?. Ann Oncol 27(2):344-52, 2016. e-Pub 2016. PMID: 26598538.
86. Antoun S, Bayar A, Ileana E, Laplanche A, Fizazi K, di Palma M, Escudier B, Albiges L, Massard C, Loriot Y. High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. Eur J Cancer 51(17):2570-7, 2015. e-Pub 2015. PMID: 26278649.
87. Kossai M, Duchemann B, Boutros C, Caramella C, Hollebecque A, Angevin E, Gazzah A, Bahleda R, Ileana E, Massard C, Vielh P, Soria JC, Besse B. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Lung Cancer 89(3):306-10, 2015. e-Pub 2015. PMID: 26160757.
88. Loriot Y, Eymard JC, Patrikidou A, Ileana E, Massard C, Albiges L, Di Palma M, Escudier B, Fizazi K. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. Eur J Cancer 51(14):1946-52, 2015. e-Pub 2015. PMID: 26208462.
89. Patrikidou A, Loriot Y, Eymard JC, Albiges L, Massard C, Ileana E, Di Palma M, Escudier B, Fizazi K. Who dies from prostate cancer?. Prostate Cancer Prostatic Dis 17(4):348-52, 2014. e-Pub 2014. PMID: 25311767.
90. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24(7):1807-12, 2013. e-Pub 2013. PMID: 23576708.
91. Ileana E, Greillier L, Moutardier V, Barlesi F. Surgical resection of liver non-small cell lung cancer metastasis: a dual weapon?. Lung Cancer 70(2):221-2, 2010. e-Pub 2010. PMID: 20828859.
92. Legodec J, Maldonado F, Ileana E, Greillier L, Dutau H, Astoul P. Pathologie pleurale. Revue des Maladies Respiratoires 2(Suppl 1):106-120, 2010. e-Pub 2010.

Review Articles

1. Adesoye T, Dumbrava EE, Raghav KS, Sahin AA, Chen H, Lee SS, Javle M, Pant S, Alhalabi O, Le X, Valero V, Pohlmann PR, Meric-Bernstam F. Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach. Clin Cancer Res 32(2):260-290, 2026. e-Pub 2026. PMID: 41283902.
2. Dumbrava EE, Frej KH, Sharon E, Tawbi H. Application and Expectations for Immune Checkpoint Blockade of LAG3 and TIGIT. Annual Review of Medicine 76(1):189-205, 2025. e-Pub 2025. PMID: 39656959.
3. Sofianidi A, Dumbrava EE, Syrigos KN, Nasrazadani A. Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets. Cancers (Basel) 16(6), 2024. e-Pub 2024. PMID: 38539474.
4. Greenbaum U, Dumbrava EI, Biter AB, Haymaker CL, Hong DS. Engineered T-cell Receptor T Cells for Cancer Immunotherapy. Cancer Immunol Res 9(11):1252-1261, 2021. e-Pub 2021. PMID: 34728535.
5. Ileana EE, Wistuba II, Izzo JG. From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma. Cancer J 21(5):413-24, 2015. e-Pub 2015. PMID: 26389767.
6. Touat M, Ileana E, Postel-Vinay S, André F, Soria JC. Targeting FGFR Signaling in Cancer. Clin Cancer Res 21(12):2684-94, 2015. e-Pub 2015. PMID: 26078430.
7. Champiat S, Ileana E, Giaccone G, Besse B, Mountzios G, Eggermont A, Soria JC. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol 9(2):144-53, 2014. e-Pub 2014. PMID: 24419410.
8. Ileana E, Champiat S, Soria JC. Immune-checkpoints: the new anti-cancer immunotherapies. Bull Cancer 100(6):601-10, 2013. e-Pub 2013. PMID: 23735730.

Editorials

1. Ileana-Dumbrava EE. Unraveling the mysteries of microsatellite instability. Sci Transl Med 13(575), 2021.
2. Ileana-Dumbrava E. Early stage EGFR-mutated lung cancer gets a targeted treatment. Sci Transl Med 12(567), 2020.
3. Ileana-Dumbrava E. PARP inhibitors unleash the antitumor immune response. Sci Transl Med 12(559), 2020.
4. Ileana-Dumbrava E. Do dendritic cells hold the key to regulating cancer antitumor immunity?. Sci Transl Med 12(551), 2020.
5. Ileana-Dumbrava E. COVID-19 and Cancer: The bad and the ugly. Sci Transl Med 12(543), 2020.
6. Ileana-Dumbrava E. Boosting immune responses against early breast cancer. Sci Transl Med 12(535), 2020.
7. Ileana Dumbrava EE, Mills GB, Yap TA. Targeting gamma secretase: has progress moved up a notch?. Ann Oncol 29(9):1889-1891, 2018. PMID: 30084907.

Abstracts

1. Lemech CR, Wei J, Chawla SP, Dumbrava EE, Sharma S, Kim SY, Schmidt AL, Bishnoi SK, Gundala S, Rastogi S, Prabash K, Jain MM, Inamdar SP, Chimote G, Sreenivasan J. A phase 1, mulitcenter, open-label, dose-escalation and expension study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SBO-154 in subjects with advanced solid tumors. ASCO Annual Meeting 44(16_suppl):TPS3161, 2026. e-Pub 2026.
2. Tsimberidou AM, Venturini J, Baysal MA, Chakraborty A, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon Ahnert J, Yap TA, Dumbrava EE, Beck J, Andersen C, Kahle M, Vining DJ, Meric-Bernstam F. Clinical outcomes of patients with PI3K pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study. ASCO Annual Meeting 44(16_suppl):3150, 2026. e-Pub 2026.
3. Saj F, Braganca Xavier C, Kang L, Le H, Rodon Ahnert J, Tsimberidou AM, Nelson BE, Dumbrava EE, Piha-Pau SA, Fu S, Champiat S, T-Y T, Yap TA, Hong DS, Meric-Bernstam F, Pant S. The phase I therapeutic landscape in pancreatic ductal adenocarcinoma: Molecular profiling and emerging strategies. ASCO Annual Meeting 44(16):e15114, 2026. e-Pub 2026.
4. Chakraborty A, Venturini J, Baysal MA, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon Ahnert J, Yap TA, Dumbrava EE, Beck J, Andersen C, Kahle M, Vining DJ, Meric-Bernstam F, Tsimberidou AM. Clinical outcomes of patients with cell cycle alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study. ASCO Annual Meeting 44(16_suppl):3149, 2026. e-Pub 2026.
5. Venturini J, Baysal MA, Chakraborty A, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon Ahnert J, Yap TA, Dumbrava EE, Beck J, Andersen C, Kahle M, Vining DJ, Meric-Bernstam F, Tsimberidou AM. Clinical outcomes of patients with TP53 pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study. ASCO Annual Meeting 44(16_suppl):3152, 2026. e-Pub 2026.
6. Reddy T, Kang L, Le H, Champiat S, Dumbrava EE, Fu Naing A, Piha-Paul SA, Pilié PG, Rodon Ahnert J, Tang TY, Tsimberidou AM, Hong DS, Goswami S, Meric-Bernstam F, Yap TA. Clinicopathologic and molecular characterization of ARID1A-mutant solid tumors using paired tissue and liquid biopsy sequencing. ASCO Annual Meeting 44(16):e15054, 2026. e-Pub 2026.
7. Baysal MA, Venturini J, Chakraborty A, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon Ahnert J, Yap TA, Dumbrava EE, Beck J, Andersen C, Kahle M, Vining DJ, Meric-Bernstam F, Tsimberidou AM. Clinical outcomes of patients with RTK-RAS pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study. ASCO Annual Meeting 44(16):3151, 2026. e-Pub 2026.
8. Siddiqui BA, Dumbrava EE, Logothetis C, Meric-Bernstam F, Subudhi SK, Naing A. A phase II clinical trial of ivonescimab (VEGFxPD-1 bispecific antibody) in patients with metastatic castration-resistant prostate cancer(mCRPC). ASCO Annual Meeting 44(16):TPS5138, 2026. e-Pub 2026.
9. Surana R, Schoenfeld AJ, Kamgar M, Dumbrava EE, Paulson AS, Becerra CR, Leidner RS, Boland PM, Hecht JR, Kundrana MN, Zhang JY, Pelster M, Yan Y, Liao Y, Shin Y, Paz-Chang H, Whangbo J, Ahrorov A, Cohen S, Fakih M. Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H–mutated unresectable advanced solid tumors. ASCO Annual Meeting 44(16_suppl), 2026. e-Pub 2026.
10. Patel MR, Dumbrava EE, H-J L, Omilusik KD, Ibitokou S, Bickers C, Kolesnichenko OA, Ferguson B, Peng S, Patel D, Hosking M, Valamehr B, Elstrom RL, Wong L, Micaily I. Preliminary phase 1 results of MICA/B-targeted CAR T cell designed to overcome solid tumor escape mechanisms and avoid the requirement for conditioning chemotherapy. ASCO Annual Meeting 44(16):2560, 2026. e-Pub 2026.
11. Pilie PG, Ozirmak Lermi N, Lubo I, Khan K, Lu W, Roemer B, Salvatierra M, Jiang M, Solis LM, Isgandarova S, Armador Molina JC, Lu H, Brown CV, Szymonowicz KA, Dumbrava EE, Ngoi N, Chen K, Meric-Bernstam F, Haymaker CL, Yap TA. Phase 1/2 trial of ATR Inhibitor berzosertib plus immune checkpoint inhibitor avelumab in patients with advanced cancers with DNA damage response (DDE) gene alterations: Tumor microenvironment - mediated pathways of resistance from correlatieve data. ASCO Annual Meeting 44(16_Suppl):3141, 2026. e-Pub 2026.
12. Derbala MH, Haymaker CL, Morris II VK, Javle MM, How JA, A-M C, Gurses SA, Stephen B, T-Y T, Champiat S, Rodon Ahnert J, Yap TA, Dumbrava EE, Piha-Paul SA, Tsimberidou AM, Fu S, Hong DS, Ashtamker N, Meric-Bernstam F, Naing A. Biomarker Study of BND-22 in combination with cemiplimab in solid tumors. ASCO Annual Meeting 44(16_suppl):TPS2676, 2026. e-Pub 2026.
13. Akcakanat A, Dumbrava EE, Evans KW, Zhang R, Zhao M, Kennon A, Zheng X, Scott SM, Yuca E, Raso G, Kong EK, Rizvi Y, Hong D, Poyurovsky MV, Lozano G, Korkut A, Meric-Bernstam F. Rezatapopt and KRAS inhibitors for the treatment of TP53 Y220C and KRAS mutant cancers. AACR Annual Meeting 86(7), 2026. e-Pub 2026.
14. Mirallas O, Marin D, Chen H, Pohlmann P, Lim B, Altan M, Hussain S, Kennon A, Daher M, Gavriliuc M, Basar R, W-L W, Yuan Y, Kebriaei P, Shpall EJ, Rodon J, Hong DS, Meric-Bernstam F, Rezvani K, Dumbrava EE. Phase I study of TROP2 CAR engineered IL-15-transduced cord blood-derived NK cells in advanced solid tumors (TROPIKANA). AACR Annual Meeting 86(8_suppl):CT294, 2026. e-Pub 2026.
15. Ahmed J, Stephan B, Kwiatkowski E, Anderson MR, Derbala MH, Salih I, Castillo L, Yang Y, Gurses SA, Yan H, Lim JT, Klekers AR, Le H, Kang L, Xu M, Tan HN, Champiat S, Tin-Yun T, Dumbrava EE, Piha-Paul SA, Rodon Ahnert J, Tsimberidou AM, Yap TA, Fu S, Hong DS, Meric-Bernstam F, Bhosale PR, Naing A. Impact of severe liver metastases on clinical response to immunotherapy in solid tumors. AACR Annual Meeting 86(8_suppl):LB429, 2026. e-Pub 2026.
16. Reddy T, Lei K, Le H, Damodaran S, Singh Ragav KP, Kopetz S, Rodon Ahnert J, Dumbrava EE, Yap TA, Williams S, Routbort MJ, Patel KP, Meric-Bernstam F. Evolution of TOP1 variants under selective pressure from topoisomerase-based therapeutics. AACR Annual Meeting 86(7_Suppl):2967, 2026. e-Pub 2026.
17. Schram A, J-S F, Italiano A, Fagotti A, Coveler A, Loriot Y, de Miguel M, Orr B, Ray-Coquard I, Tan T, Wiesweg M, Greystoke A, Grimison P, LeDuke K, Schmid A, Jalota D, Fellous M, Dumbrava EE. The pivotal PYNNACLE phase 2 trial assessing rezatapopt, a selective p53 reactivator, in patients with advanced or metastatic solid tumors harboring a TP53 Y220C mutation: Interim analysis of patients with ovarian cancer. Society of Gynecologic Oncology (SGO) Annual Meeting 208:S35-S36, 2026. e-Pub 2026.
18. J-S F, Dumbrava EE, Italiano A, Fagotti A, Coveler AL, Loriot Y, De Miguel Lukien MJ, Orr B, Ray-Coquard I, Tan TJ, Wiesweg M, Fontana E, Greystoke A, Grimison P, Leduke K, Schmid A, Jalota D, Fellous M, Schram AM. Rezatapopt, a selective p53 reactivator, in advanced or metastatic solid tumours with a TP53 Y220C mutation: interim efficacy results from patients with ovarian cancer in the phase 2 PYNNACLE trial. European Gynaecological Oncology Congress 36(2), 2026. e-Pub 2026.
19. Chandana SR, Kelley RK, Fin RS, Dumbrava EE, Ikeda M, Hamm JT, Grewal JS, Gutierrez M, Maruki Y, Nakajima TE, Ikoma T, M Weinstein M, Mekan SF, Abou-Alfa GK. A phase 1, first-in-human, multicenter study of ZW251, a novel glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in participants with hepatocellular carcinoma (HCC). ASCO Gastrointestinal Cancers Symposium 44(2 suppl):TPS608, 2026. e-Pub 2026.
20. Piha-Paul SA, Lavasani S, Dayyani F, Goel S, Tsimberidou A, Ibrahim N, Barcenas C, Ilheme A, Rodon J, Dumbrava EE, Hennessy K, Peng P, Sun C, Wang H, Xu R, Fan J, Meric-Bernstam F. Tinengotinib in advanced or metastatic HR+/HER2- and TNBC: efficacy and biomarker correlative analysis from a phase Ib/II study. San Antonio Breast Cancer Symposium 32(4 Suppl):6-14, 2025. e-Pub 2025.
21. Wu T, Teymur A, Derbala MH, Stephen B, Castillo L, Yang Y, Gurses SA, Tan HN, Dumbrava EE, Tsimberidou AM, Champiat S, Hajjar J, Tang TY, Yap TA, Rodon Ahnert J, Piha-Paul SA, Fu S, Hong DS, Meric-Bernstam F, Naing A. Immune Complex Profiling Identifies Biomarkers of Response to Immune Checkpoint Inhibitors Across Cancers. ESMO Immuno-Oncology Congress, 2025. e-Pub 2025.
22. Braganca Xavier C, Stephen B, Gurses S, Gocio M, Kaseb M, Yang Y, Cimo A, Derbala M, Tang TY, Champiat S, Pohlmann P, Gouda M, Tan H, Torrado Martin C, Rodon J, Yap T, Dumbrava EE, Piha-Paul S, Tsimberidou AM, Fu S, Hong D, Meric-Bernstam F, Naing A. A phase 1 dose escalation and dose expansion trial of NP-101 in patients with advanced solid tumors. SITC Annual Meeting 13(Suppl 2):A1–A1534, 2025. e-Pub 2025.
23. George G, Piha-Paul SA, Rodon Ahnert J, Dumbrava EE, Tsimberidou AM, Appleton G, Yap TA, Meric-Bernstam F, Hong DS. Dietary links with symptoms in early-phase immune checkpoint combinations trials. ASCO Quality Care Symposium 21(10 suppl):341, 2025. e-Pub 2025.
24. Doerfler AM, Dumbrava EE, Yuan Y, Pickett-Gies C, Gore S, Westin SN, Ajani JA, A-M C, Fu S, Lee C, Lin Q, Fleming R, Yap TA, Keyomarsi K, Meric-Bernstam F. Trial in Progress: Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/ Amplified Gastric/ Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 24(10 Suppl):B009, 2025. e-Pub 2025.
25. Gouda MA, King L, Tang TY, Dumbrava EE, Champiat S, Piha-Paul SA, Pohlmann PR, Naing A, Fu S, Tsimberidou AM, Rodon J, Yap TA, Meric-Bernstam F, Hong DS. Discrepancies Between Calculated and Actual Creatinine Clearance: A Phase 1 Trial Unit Experience. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 24(10 Suppl):C063, 2025. e-Pub 2025.
26. Minchom AR, Culm K, Makris L, Johnson ML, Sommerhalder D, Henry J, Garralda E, Merchan JR, Yang M, A-L G, Burzyn D, Z-Y Y, Wei R, Mascola J, Abbadessa G, Nabel G, Dumbrava EE. A phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors. ESMO Congress 36(Suppl 2):1584TiP, 2025. e-Pub 2025.
27. Yeku O, Sullivan RJ, Sharma MR, Kurnit KC, Patel MR, Dumbrava EE, Rasco D, Vaena D, Gaillard S, Noonan AM, Hays J, Lorber I, Zimmer-Strulov L, Frishman I, Ferre PJ, Barbiro I, Cojocaru G, Ophir E, Mahler M, O'Malley. COM701 in ovarian cancer: A pooled analysis of 3 phase I clinical trials. ESMO Congress 36(Suppl2):1196P, 2025. e-Pub 2025.
28. Tan HN, Yap TA, Rodon J, Stephan B, Dumbrava EE, Piha-Paul S, Fu S, Champiat S, Akhave N, Gillison M, Heymach JV, Hong D, Meric-Bernstam, Naing A. Clinical Outcomes and Biomarker Correlates of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Novel Immunotherapies in Phase 1 Trials. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 24(10 Suppl):B084, 2025. e-Pub 2025.
29. Schmidt S, Baysal M, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon J, Yap TA, Dumbrava EE, Beck J, Meric-Bernstam F, Tsimberidou AM. Concordance analysis of DNA and RNA profiling: Results of the MD Anderson IMPACT2 study in precision oncology. ESMO Congress 36(Suppl 2):990P, 2025. e-Pub 2025.
30. Venturini J, Baysal M, Chakraborty A, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon J, Yap TA, Dumbrava EE, Beck J, Liu Y, Zhang J, Futreal A, Meric-Bernstam F, Tsimberidou AM. MD Anderson IMPACT2 study: Mutation enrichment analysis by tumor type and gene co-occurrence patterns in patients with DDR and non-DDR alterations. ESMO Congress 36(Suppl 2):988P, 2025. e-Pub 2025.
31. Fu S, Tan HN, Rodon J, Dumbrava EE, Tsimberidou AM, Karp D, Raghav K, Kee B, Le P, Morelli MP, Parseghian C, Yuan Y, Chowdhury M, Schauer I, Peng J, Naing A, Hong DS, Overman MJ, Meric-Bernstam F. Phase I study of NovoTTF-100L(P) in combination with chemotherapy in patients with predominant hepatic metastatic colorectal cancer. ESMO Congress 36(Suppl 2):983P, 2025. e-Pub 2025.
32. Adesoye T, Elders ML, Le H, Hong D, Belay SY, Rodon JA, Dumbrava EE, Naing A, Piha-Paul SA, Fu S, Tang TY, Tsimberidou AM, Tam AL, Murthy R, McNeill LH, Meric-Bernstam F. Research biopsy participation and safety in cancer therapeutic trials. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 24(10 Suppl):C065, 2025. e-Pub 2025.
33. Reddy TP, Kang L, Le H, Damodaran S, Raghav K, Kopetz S, Rodon Ahnert J, Dumbrava EE, Yap TA, Williams S, Routbort MJ, Patel KP, Meric-Bernstam F. Emergence of TOP1 mutations as a potential biomarker of resistance to topoisomerase-targeting regimens. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 34(10 Suppl):A041, 2025. e-Pub 2025.
34. Fellous M, Green C, Prince P, Shen J, Cho-Phan C, Langeman S, Li G, Graf R, Dumbrava EE, Schram AM. Natural history and prognostic value of TP53 Y220C mutation in advanced solid tumors: A real-world study. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 24(10 Suppl):C046, 2025. e-Pub 2025.
35. Bose R, Park H, Dumbrava EE, Freedman R, Abraham J, Davis AA. Neratinib in combination with antibody–drug conjugates for patients with metastatic cancer. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 24(10 Suppl):B060, 2025. e-Pub 2025.
36. Uzunparmak B, Su F, Johnson AM, Shaw KR, Kong EK, Korkut A, Braganca-Xavier C, Yuan Y, Fowler N, Paradiso F, Kontselidze L, Butusova A, Bagaev A, Dumbrava EE, Rodon-Ahnert J, Hong DS, Fu S, Yap TA, Naing A, Piha-Paul SA, Ferrarotto R, Iorgulescu B, Kulkarni S, Patel KP, Meric-Bernstam F. Clinical Utility of Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 24(10 Suppl):C054, 2025. e-Pub 2025.
37. Fu S, Braganca Xavier C, Keyomarsi K, Wang Y, Ferry-Galow K, Wilsker D, Paradiso F, Kushnarev V, Yuan Y, Previs RA, Elias AD, Carvajal R, George TJ, Yao S, Yuan Y, Dumbrava EE, Piha-Paul SA, Tsimberidou AM, Rodon Ahnert J, Westin S, Meric-Bernstam F. Biomarker analyses of WEE1 inhibition in patients with refractory CCNE1 amplified solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 24(10 Suppl):B009, 2025. e-Pub 2025.
38. Venturini J, Baysal MA, Chakraborty A, Yap TA, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon Ahnert J, Dumbrava EE, Beck J, Andersen C, Kahle M, Vining DJ, Meric-Bernstam F, Tsimberidou AM. Clinical outcomes of patients with or without DNA repair pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study. ASCO Annual Meeting 43(16 Suppl):2660, 2025. e-Pub 2025.
39. Subbiah V, McGregor BA, Dumbrava EE, Italiano A, Garralda E, Shreenivas AV, Shitara K, Zhang AY, Theron M, Hiemeyer F, Mussi CE, Daniele G. panSOHO: Phase II trial of BAY 2927088 in patients with unresectable or metastatic solid tumors other than NSCLC with HER2‑activating mutations. ASCO Annual Meeting 43(16 Suppl):TPS3185, 2025. e-Pub 2025.
40. Schram AM, Clay TD, Prenen H, Park JJ, Lunger L, Hussain J, Maier D, Kitano S, Dumbrava EE, Kim HD, Ponz-Sarvise M, Guo Y. Beamion PANTUMOR-1: A phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2-mutated or overexpressed/amplified solid tumors. ASCO Annual Meeting 43(16 Suppl):TPS3187, 2025. e-Pub 2025.
41. Su F, Uzunparmak B, Johnson A, Shaw KR, Fowler NH, Kontselidze L, Bagaev A, Butusova A, Dumbrava EE, Rodon Ahnert J, Fu S, Hong DS, Yap TA, Naing A, Piha-Paul SA, Ferrarotto R, Iorgulescu B, Kulkarni S, Patel K, Meric-Bernstam F. Clinical utility of comprehensive transcriptome testing in advanced solid tumors. ASCO Annual Meeting 43(16 Suppl):3072, 2025. e-Pub 2025.
42. Schram, AM, Frenel, JS, Johnson, M, Italiano, A, Kummar, S, Coveler, A, Spira, AI, Body, A, Fontana, E, Garralda, E, Greystoke, A, Millward, M, Scambia, G, Tan, DP, Fellous, M, Dumbrava, EE, Lopes, G. PYNNACLE phase 2 clinical trial of rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. ASCO Annual Meeting 43(16 Suppl):TPS11581, 2025. e-Pub 2025.
43. Koksoy, AA, Uzunparmak, B, Raso, G, Perez, R, Wang, L, Yildirim, O, Abbadessa, G, Masciari, S, Barrientos Toro, E, Batra, H, Parra Cuentas, ER, Rizvi, YQ, Lazcano Segura, RN, Ding, Q, Champiat, S, Meric-Bernstam, F, Haymaker, CL, Dumbrava, EE. Characterization of the immune microenvironment and spatial phenotypes across HER2 subtypes in advanced or metastatic breast cancer. ASCO Annual Meeting 43(16 Suppl):1037, 2025. e-Pub 2025.
44. Dumbrava EE, El-Khoueiry A, Samol J, Almhanna K, Hong JY, Chenard-Poirier M, B-Y R, Goh BC, Kefsi A, Perez RP, Meng R, Masciari S, Abbadessa G, Pasquier B, Guillemin-Paveau H, Lepine L, Zhang Y, Lim DW. Phase 1/2, open-label, first-in-human study of the anti-GPC3 T-cell engager SAR444200 in patients with advanced solid tumors: Updated efficacy and biomarker analysis. ASCO Annual Meeting 43(16 Suppl):2521, 2025. e-Pub 2025.
45. Dumbrava EE, Culm K, Makris L, Johnon ML, Sommerhalder D, Henry JT, Michom AR, Garralda Cabanas E, Yang M, Cotreau M, A-L G, Burzyn D, Z-Y Y, Wei R, Mascola J, Abbadessa G, Nabel G. A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors. ASCO Annual Meeting 43(16 Suppl):TPS2670, 2025. e-Pub 2025.
46. Tan HN, Haj Frej KB, Kang L, Le H, Sharon E, Champiat S, Meric-Bernstam F, Vossella FV, Naing A, Altan M, Dumbrava EE. Association of immune-related adverse events with survival and treatment outcomes in thymic tumors treated with immune checkpoint inhibitors. ASCO Annual Meeting 43(16 Suppl):8111, 2025. e-Pub 2025.
47. Uk Lim J, Kang L, Le H, Tang TY, Champiat S, Dumbrava EE, Le X, Naing A, Piha-Paul A, Rodon Ahnert J, Tsimberidou AM, Yap TA, Fu S, Meric-Bernstam F, Hong DS. Therapeutic responses in 555 advanced NSCLC patients enrolled in phase I studies at MD Anderson Cancer Center. ASCO Annual Meeting 43(16 Suppl):8635, 2025. e-Pub 2025.
48. Braganca Xavier C, Lei K, Le Hung Kahle M, Tsimberidou AM, Naing A, Dumbrava EE, Rodon Ahnert J, Pohlmann PR, Piha-Paul SA, Fu S, Champiat S, Yap TA, T-Y T, Kopetz S, Meric-Bernstam F, Hong DS. Colorectal cancer with gene fusions: Navigating the genomic landscape and treatment selection in a phase I unit. ASCO Annual Meeting 43(16 Suppl):3558, 2025. e-Pub 2025.
49. Fox DA, Bhamidipati D, Lin HY, Hinkle LE, Pham CT, Rodon Ahnert J, Champiat S, Dumbrava EE, Fu S, Kang L, Le H, Meric-Bernstam F, Naing A, Piha-Paul SA, Pohlmann PR, Tang TY, Tsimberidou AM, Yap TA, Huey RW, Hong DS. Outcomes of young-onset colorectal cancer vs late-onset colorectal cancer patients on phase 1 matched and non-matched therapies. ASCO Annual Meeting 43(16 Suppl):3549, 2025. e-Pub 2025.
50. Dumbrava EE, Mathews CA, O'Neil B, Swiecicki P, Gaillard S, Starodub A, LoRusso P, Moroney M, Thomas JS, Lakhani NJ, Oh C, Andreu C, Lee L, Campbell JI, Bowler TG, Ozuna A, Lee J, Drutman S, Friedman CF. Preliminary results from a first-in-human, phase I/II study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced solid tumors. ASCO Annual Meeting 43(16 Suppl):3012, 2025. e-Pub 2025.
51. Frenel JS, Zagami P, Lopes G, Grimison P, Johnson ML, Tan DS, Kummar S, Leduke K, Fellous M, Dumbrava EE, Schram A. PYNNACLE phase II study of rezatapopt in patients with advanced solid tumors, including breast cancers, and a TP53 Y220C mutation. ESMO Breast Cancer Congress 10(Suppl 4):150TiP, 2025. e-Pub 2025.
52. Torrado C, Tomczak K, Dumbrava EE, Sun B, Ngoi N, Arrechedera C, Para ER, Rodon Anhert J, Piha-Paul SA, Tsimberidou AM, Fu S, Naing A, Pohlmann PR, Hong DS, Meric-Bernstam F, Msaouel P, Haymaker CL, Yap TA. Clinical and translational study of the TGF-β monoclonal antibody SAR439459 in combination with the PD-1 inhibitor cemiplimab for patients (pts) with advanced solid tumors: Results from the phase 1b TACTIC trial. AACR Annual Meeting 85(8 Suppl):CT046, 2025. e-Pub 2025.
53. Braganca Xavier C, Andersen C, Lim JT, Slade JH, Bean SA, Kang L, Le H, Tsimberidou A, Naing A, Hong D, Dumbrava EE, Rodon J, Pohlmann P, Piha-Paul S, Champiat S, Yap TA, Tang TY, Meric-Bernstam F, Fu S. Modulating treatment outcomes of patients with solid tumors in immunotherapy trials: a drug interaction analysis from a phase I unit. AACR Annual Meeting 85(8 Suppl):5952, 2025. e-Pub 2025.
54. George GC, Lee H, Piha-Paul SA, Dumbrava EE, Tsimberidou A, Fu S, Appleton G, Noor L, Rodon J, Yap TA, Meric-Bernstam F, Hong DS. Food choices of patients with advanced cancer at start of early-phase combination trials with immune checkpoint blockade. AACR Annual Meeting 85(8 Suppl):809, 2025. e-Pub 2025.
55. Davis AA, Park H, Dumbrava EE, Uboha NV, Kalyan A, Dayyani F, Arora M, Villalona-Calero MA, Mahdi HS, Patel RA, Backes F, Porzel J, Hensing WL, Pickett C, Ma CX, Bose R. Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495). AACR Annual Meeting 85(8 Suppl):CT071, 2025. e-Pub 2025.
56. Dumbrava EE, Rodrigues II, Salkeni MA, Giordano A, Chen C, Sahota S, Perez EA, Yu T, Rosenthal K, Balacy K, Cai D, Ptacek J, Xu L, Colburn D, Ackerman SE, Alonso MN, Kenkel JA, Vandross A. BDC-3042, a first-in-class Dectin-2 agonist, in patients with advanced malignancies: Results from the first-in-human dose-escalation study. AACR Annual Meeting 85(8 Suppl):CT154, 2025. e-Pub 2025.
57. Dumbrava EE, Iqbal S, Turcotte S, Botta G, Schlechter B, Ku G, Hosein P, Saibil S, Gavriliuc M, Apostolopoulou M, Giwa M, MacGregor H, Moss K, Panna E, Murugappan S, Sohal D. A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors. Spring Scientific Cellular Therapy for Solid Tumors, 2025. e-Pub 2025.
58. Ngoi NYL, Rodon J, Dumbrava EE, Garmezy B, Hong DS, Piha-Paul S, Tsimberidou AM, Fu S, Naing A, Pohlmann PR, Tang TY, Clemente H, Rhudy J, Valladolid C, Salguero C, Velez NA, Tran HT, Meric-Bernstam F, Yap TAA. TalaCom: Phase Ib investigator-initiated trial combining talazoparib and axitinib in patients with DNA damage response mutated cancers or BRCA1/2 wildtype ovarian cancer incorporating prospective intrapatient dose titration. ESMO Targeted Anticancer Therapies (TAT) Congress 10(Suppl 2):104186, 2025. e-Pub 2025.
59. Almhanna K, Hong JY, Chenard-Poirier M, B-Y R, DW-T L, El-Khoueiry AB, B-C G, Samol J, Kefsi A, Perez R, Meng R, Masciari S, Abbadessa G, Guillemin-Paveau H, Lepine L, Zhang Y, Dumbrava EE. Phase I/II, open-label, first-in-human study of the anti-GPC3 T cell engager SAR444200 in patients with advanced solid tumors: Updated safety and pharmacokinetic analysis. ESMO Targeted Anticancer Therapies (TAT) Congress 10(Suppl 4):104165, 2025. e-Pub 2025.
60. J-S F, Zagami P, Lopes G, Grimison P, Johnson ML, Tan DS, Kummar S, Leduke K, Fellous M, Dumbrava EE, Schram A. PYNNACLE phase II study of rezatapopt in patients with advanced solid tumors, including breast cancers, and a TP53 Y220C mutation. ESMO Targeted Anticancer Therapies (TAT) Congress 10(Suppl 4):104703, 2025. e-Pub 2025.
61. Calvo E, Moreno Garcia V, Oh D-Y, Ruy MH, Garralda E, Chumg W-P, Bai L-Y, Rojas Laimito KI, Yildirim O, Masciari S, Mi G, Wang L, Carene D, Gailhac S, Perez R, Kanlikilicer P, Buday B, Rharbaoui F, Abbadessa G, Dumbrava EE. Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results. ESMO Targeted Anticancer Therapies (TAT) Congress 10(Suppl 2):104199, 2025. e-Pub 2025.
62. Stephen B, Kwiatkowski E, Anderson MR, Derbala MH, Salih I, Castillo L, Yang Y, Gurses SA, Lim JT, Klekers AR, Le H, Kang L, Xu M, Ahmed J, Tan HN, Champiat S, Tang TY, Dumbrava EE, Fu S, Piha-Paul SA, Rodon Ahnert J, Tsimberidou AM, Yap T, Yuan Y, Hong DS, Meric-Bernstam F, Bhosale P, Naing A. Impact of liver metastases and systemic biomarkers on immunotherapy response and survival outcomes in patients with solid tumors. AACR Immuno-Oncology Conference, 2025. e-Pub 2025.
63. Dumbrava EE, Iqbal S, Turcotte S, Botta G, Schlechter B, Ku G, Hosein P, Saibil S, Gavriliuc M, Apostolopoulou M, Giwa M, Moss K, Murugappan S, Sohal D. A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors. ASCO Gastrointestinal Cancers Symposium 43(4 Suppl):828, 2025. e-Pub 2025.
64. Oh D, Vu P, Baranda JC, Henry J, Rodriguez Rivera II, Eskew JD, Belani R, Martinez-Prieto M, McCaigue J, Namini H, Haag S, Bauer D, Martin C, Gregovics C, Murphy A, Coronella J, Shedlock DJ, Dumbrava EE. Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies. ESMO Immuno-Oncology Congress 24(Suppl):100861, 2024. e-Pub 2024.
65. Dumbrava EE, Kummar S, Johnson M, Le Duke K, Qin YG, Fellous M, Schram AM. Phase 1 Analysis from the PYNNACLE Phase 1/2 Study of Rezatapopt in the Subgroup of Patients with Advanced Breast Cancer Harboring a TP53 Y220C Mutation. San Antonio Breast Cancer Symposium 31(12 Suppl):P3-12-27, 2024. e-Pub 2024.
66. Gouda M, Gonugunta A, Dumbrava EE, Yap TA, Rodon J, Piha-Paul SA, Pohlmann PR, Damodaran S, Murthy R, Valero V, Mouabbi J, Tripathy D, Sahin A, Chen H, Meric-Bernstam F. HER2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. San Antonio Breast Cancer Symposium 31(12 Suppl):P1-01-27, 2024. e-Pub 2024.
67. Stephen B, Anderson M, Kwiatkowski E, Derbala M, Yang Y, Lim J, Klekers A, Dumbrava EE, Fu S, Piha-Paul S, Rodon J, Tsimberidou A, Yap T, Yuan Y, Hong D, Meric-Bernstam F, Bhosale P, Naing A. Impact of liver metastasis on immunotherapy in patients with solid tumors. SITC Annual Meeting 12(Suppl 3):837, 2024. e-Pub 2024.
68. Dumbrava EE, Iqbal S, Turcotte S, Botta G, Schlechter B, Ku G, Hosein P, Saibil S, Gavriliuc M, Apostolopoulou M, Giwa M, Moss K, Murugappan S, Sohal D. A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors. SITC Annual Meeting 12(Suppl 3):1472, 2024. e-Pub 2024.
69. Ptacek J, Luo A, Peaerson C, Dumbrava EE, Drago J, Du M, Mangeshkar M, Yin M, uy T, Kim H, Tomaro J, Gourley L, Perez E, Alonso M, Colburn D, Xu L. Key learnings from BDC-1001 phase 1 FIH dose escalation trial inform next-generation ISACs. SITC Annual Meeting 12(Suppl 3):30, 2024. e-Pub 2024.
70. Dumbrava EE, Friedman C, Hamilton E, Chen C, Sumrow B, JeBailey L, Klempner S. XMT-2056: A Phase 1 Study of a HER2-directed STING agonist Antibody Drug Conjugate (ADC) in HER2+ Solid Tumors. SITC Annual Meeting 12(Suppl 3):654, 2024. e-Pub 2024.
71. Coleman N, Ngoi NYL, Nguyen D, Nelson B, Dumbrava EE, Fu S, Hong DS, Karp D, Naing A, Piha-Paul SA, Rodon J, Tsimberidou A, Lim B, Pohlman P, Meric-Bernstam F, Litton JK, Arun B, Yap TA. Poly(ADP-Ribose) Polymerase (PARP) inhibition in metastatic breast cancer: comparison of therapeutic outcomes between patients with BRCA1/2 mutations and other alterations. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 211(Suppl 1):337, 2024. e-Pub 2024.
72. Minchom AR, Culm K, Garmey E, Makris L, Johnson ML, Sommerhalder D, Garralda E, Henry J, Yang M, Mei L, Cotreau MM, Goenaga AL, Burzyn D, Yang ZY, Wei R, Chhaljani V, Mascola J, Nabel G, Dumbrava EE. A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies. ESMO Congress 35(S2):S530, 2024. e-Pub 2024.
73. Fu S, Tsimberidou AM, Dumbrava EE, Yuan Y, McLeod S, Karp D, Rodon J, Yu H, Peng J, Daniel LM, Piha-Paul SA, Naing A, Meric-Bernstam F. Phase I Study of Pamiparib and Cabozantinib in Patients with Metastatic Solid Tumors Harboring Homologous Recombination Deficiency (HRD). ESMO Congress 35(S2):S502, 2024. e-Pub 2024.
74. Tsimberidou, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon J, Yap TA, Karp DD, Dumbrava EE, Heymach J, Ajani JA, Cartwright C, Beck J, Andersen CR, Kahle M, Vining DJ, Ross JS, Chao CY, Berry DA, Meric-Bernstam F. Final Results of IMPACT 2, a Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer at MD Anderson Cancer Center. ESMO Congress 35(S2):S506-S507, 2024. e-Pub 2024.
75. Moreno Garcia V, Oh DY, Ryu MH, Calvo E, Garralda E, Chung WP, Bai LU, Rojas KI, Wang L, Kanlikilicer P, Buday B, Rharbaoui F, Abbadessa G, Dumbrava EE. Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results. ESMO Congress 35(S2):S518, 2024. e-Pub 2024.
76. Schram AM, Lopes G, El-Khoueiry AB, Fontana E, Karasic TB, Kummar S, LoRusso PM, Gregorc V, Millward M, Ponce Aix S, Richardson DL, Perez DR, Spira AI, Tan DSP, Thompson JA, Uprety D, Fellous M, Qin YG, Dumbrava EE. PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation. ESMO Congress 35(S2):S535-S536, 2024. e-Pub 2024.
77. Corr BR, Dumbrava EE, Spira AI, Willmott L, Butrynski JE, Tse KY, j P, MekanS, Mocci S, Wu T, Santin AD. Efficacy and safety of sacituzumab govitecan (SG) in patients with advanced/metastatic endometrial cancer (EC): Updated results from TROPiCS-03. ESMO Congress 35(S2):S558, 2024. e-Pub 2024.
78. Torrado Martin C, Rai K, Moawad M, Dumbrava EE, Fu S, Hong D, Karp D, Meric-Bernstam F, Naing A, Pohlmann P, Rodon Ahnert J, Tsimberidou A, Yap T, Said R, Pelosof L, Piha-Paul S. A phase 1 study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer (NCI number 10449). ASCO Annual Meeting 42(16 Suppl):TPS3182, 2024. e-Pub 2024.
79. Gouda M, Shunyakova J, Naing A, Dumbrava EE, Hong D, Yuan Y, Yang P, Myers A, Liang Y, Ping J, Karp D, Tsimberidou A, Rodon Ahnert J, Yap T, Piha-Paul S, Meric-Bernstam F, Fu S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ASCO Annual Meeting 42(16 Suppl):3152, 2024. e-Pub 2024.
80. Dumbrava EE, Thompson J, Jensen-smith A, Ranger A, Fan P, Katina S, Duhard P, Paulson A. DUET-01: A first-in-human, phase 1/2 study of BOXR1030 in patients with advanced glypican-3-positive solid tumors. ASCO Annual Meeting 42(16 Suppl):TPS2681, 2024. e-Pub 2024.
81. Tsimberidou A, Fu S, Hong D, Piha-Paul S, Naing A, Rodon Ahnert J, Yap T, Karp D, Dumbrava EE, Heymach J, Ajani J, Cartwright C, Beck J, Andersen C, Kahle M, Vining D, Ross J, Chao C, Berry D, Meric-Bernstam F. Results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center. ASCO Annual Meeting 42(16 Suppl):3153, 2024. e-Pub 2024.
82. Dumbrava EE, Kennon A, Balema W, Lim C, Vempati S, Stergiopoulos S, Richardson D. A first-in-human, phase 1 study evaluating oral TACC3 inhibitor, AO-252, in advanced solid tumors. ASCO Annual Meeting 42(16 Suppl):TPS3176, 2024. e-Pub 2024.
83. Dumbrava EE, Olson D, Saibil S, Sohal DP, Iqbal S, Urgelles A, Apostolopoulou M, Mueller A, Moss K, Adib D, Schlecter B. A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced, or metastatic claudin 18.2+ solid tumors. ASCO Annual Meeting 42(3), 2024. e-Pub 2024.
84. Gouda M, Lin H, Kang L, Le H, Dumbrava EE, Fu S, Karp D, Tsimberidou A, Naing A, Piha-Paul S, Pohlmann P, Rodon Ahnert J, Yap T, Meric-Bernstam F, Hong D. Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors. ASCO Annual Meeting 42(16 Suppl):3099, 2024. e-Pub 2024.
85. Tao D, Nardo M, Hong Leung C, Lin H, Kang L, Le H, Dumbrava EE, Hong D. The role of obesity on outcomes of adoptive cellular therapy in solid tumors. ASCO Annual Meeting 42(16):2544, 2024. e-Pub 2024.
86. Chenard-Poirier M, Almhanna K, Lim D, El-Khoueiry A, Samol J, Ryoo B-Y, Yong Hong J, Meng R, Abbadessa G, Masciari S, Kefsi A, Zhang Y, Guillemin-Paveau H, Pasquier B, Lepine L, Dumbrava EE. Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors. ASCO Annual Meeting 42(16 Suppl):2579, 2024. e-Pub 2024.
87. Mirallas O, Lin R, Alvarez-Ballesteros P, Campbell E, Le H, Dumbrava EE, Yap T, Hong D, Meric-Bernstam F, Thall P, Rodon Ahnert J, Martin Cullell B. Total toxicity burden as a practical tool to quantify the overall severity of multiple adverse events in clinical trials. ASCO Annual Meeting 42(16 Suppl):3156, 2024. e-Pub 2024.
88. Gaillard S, Starodub A, O'Neil B, Mathews C, Dumbrava EE, Friedman C, Swiecicki P, Oh C, Andreu C, Lee L, Campbell J, Bowler T, Drutman S, LoRusso P. A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer. ASCO Annual Meeting 42(16 Suppl):TPS3181, 2024. e-Pub 2024.
89. Salkeni M, Vandross A, Dumbrava EE, Giordano A, Chen C, Kenkel J, Cai D, Xu L, Alonso M, Ackerman S, Yu T, Colburn D, Perez E, Wilks S. A phase 1/2 study of BDC-3042, a novel dectin-2 agonistic antibody, in patients with advanced cancers. ASCO Annual Meeting 42(16 Suppl):TPS2695, 2024. e-Pub 2024.
90. Sharma M, Noonan A, Vaena D, Dumbrava EE, Wang J, Rasco D, Papadopoulos K, Shreenivas A, Ferre P, Ophir E, Barbiro Cojocaru G, Mahler M, Adewoye A, Patel M. Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases. ASCO Annual Meeting 42(16 Suppl):3597, 2024. e-Pub 2024.
91. George G, Piha-Paul S, Dumbrava EE, Subbiah V, Fu S, Tsimberidou A, Pant S, Appleton G, Noor L, Yap T, Rodon Ahnert J, Meric-Bernstam F, Cleeland C, Mendoza T, Hong D. Patient-reported symptom interference with activity- and mood-related functioning prior to start of an early-phase oncology combination trial including immune checkpoint blockade. ASCO Annual Meeting 42(16 Suppl):12084, 2024. e-Pub 2024.
92. Dumbrava EE, Kennon AM, Murthy RK, Montazari EJ, Tawbi H, Li J, Lang F, Sanchez G, Wang J, Glitza IC, O'Brien BJ, Beckham T, Swanson T, Tom MC, Vu UM, Darko TT, Cai T, Shah K, Meric-Bernstam F, Rodon J. A phase II study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in patients with HER2-positive metastatic solid tumors and metastases to brain (TUCATEMEB). AACR Annual Meeting 84(7 Suppl):CT289, 2024. e-Pub 2024.
93. Davis AA, Dumbrava EE, Kalyan A, Uboha NV, Mahdi HS, Patel RA, Dayyani F, Porzel J, Hensing WL, Ma CX, Bose R, Park H. Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495). AACR Annual Meeting 84(7 Suppl):CT159, 2024. e-Pub 2024.
94. Dumbrava EE, Iwamoto FM, Agulnik M, Milhem M, Tolcher AW, Chugh R, Demeure MJ, Mita A, Demel K, Diamond M, Mirakhur B, Wilson L, Oganesian A, Chan D, Keer HN, Taylor J, Sims MJ, Biondo A, Jueliger S, Spira A. Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53. AACR Annual Meeting 84(7 Suppl):CT066, 2024. e-Pub 2024.
95. Uzunparmak B, Su F, Johnson AM, Nomie K, Fowler N, Kontselidze L, Bagaev A, Butusova A, Dumbrava EE, Rodon-Ahnert J, Fu S, Hong DS, Yap TA, Naing A, Piha-Paul SA, Karp DD, Pohlmann PR, Tsimberidou AM, Patel KP, Meric-Bernstam F. Comprehensive genomic and transcriptomic analysis to guide therapy for patients with metastatic solid tumors. AACR Annual Meeting 84(7 Suppl):939, 2024. e-Pub 2024.
96. Yap T, Dumbrava EE, Rodon Ahnert J, Tsimberidou A, Hong D, Piha-Paul S, Karp D, Fu S, Naing A, Pohlmann P, Rhudy J, Berenji-Jalaei S, Cole A, Valladolid C, Dufner D, Bockorny B, Bullock A, Fein D, Buchbinder E, Choudhury A, Haddox C, Lee E, Wulf G, Ivy P, Said R, Shapiro G, Meric-Bernstam F. NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations. AACR Annual Meeting 84(7 Suppl):CT042, 2024. e-Pub 2024.
97. Dumbrava EE, Montazari EJ, Vu UM, Cai T, Altan M, Ibrahim NK, Yeboa DN, Li J, Lang FF, Sanchez G, Glitza IC, O'Brien BJ, Murthy RK, Wang J, Darko TT, Velazquez D, Shah K, Meric-Bernstam F, Tawbi H, Rodon J. Phase II study of pembrolizumab in combination with lenvatinib in patients with triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and other tumor types and brain metastases. AACR Annual Meeting 84(7 Suppl):CT292, 2024. e-Pub 2024.
98. Schlechter B, Dumbrava EE, George M, Saibil S, Butler M, Giordano A, Surana R, C-Y L, Weiss J, Pieke B, Gavriliuc M, Lichtenstein, Apostolopoulou M, Burke C, Qureshi B, Adib D, Olson D. A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. ASCO Gastrointestinal Cancers Symposium 42(3 Suppl):747, 2024. e-Pub 2024.
99. Dumbrava EE, Sohal D, Olson D, Saibil S, Urgelles A, Apostolopoulou M, Mueller A, Moss K, Adib D, Schlechter B, Iqbal S. First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors. ASCO Gastrointestinal Cancers Symposium 42(3 Suppl):TPS419, 2024. e-Pub 2024.
100. Bhamidipati D, Haro-Silerio J, Dumbrava EE, Fu S, Hong D, Karp D, Naing A, Pant S, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Johnson A, Lee M, Raghav K, Morris V, Overman M, Kopetz S, Meric-Bernstam F, Yap T, Dasari A. Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations. ASCO Gastrointestinal Cancers Symposium 42(3 Suppl):134, 2024. e-Pub 2024.
101. Piha-Paul S, Xu B, Fan Y, Yuan Y, Lavasani S, Mortimer J, Goel S, Tsimberidou A, Ibrahim N, Abouharb S, Barcenas C, Iheme A, Karp D, Rodon Ahnert J, Dumbrava EE, Fan J, Peng P, Sun C, Wang H, Hennessy K, Fu X, Xu R, Ni S, Wu F, Meric-Bernstam F. The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC. San Antonio Breast Cancer Symposium 84(9 Suppl):RF01-07, 2023. e-Pub 2023.
102. Dumbrava EE, Albanell Mestres J, Ascierto PA, Blay J-Y, Champiat S, Cortes Salgado A, Deleuze A, GilMartin M, Heeke A, Italiano A, Kang Y-K, Lee J, K-W L, Losurdo A, Magni M, Moore K, Oaknin Benzaquen A, Ortegof Zabalza I, Park H. Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer. SITC Annual Meeting 11(Suppl 1):716, 2023. e-Pub 2023.
103. Olson D, Dumbrava EE, George M, Saibil S, Butler M, Giordano A, Pieke B, Gavriliuc M, Lichtenstein E, Geisberger J, Apostolopoulou M, Moss K, D'Arcy K, Dang S, Adib D, Schlechter B. A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. SITC Annual Meeting 11(Suppl 1):654, 2023. e-Pub 2023.
104. Olson D, Dumbrava EE, Saibil S, Gutierrez M, Iqbal S, Sohal D, Apostolopoulou M, Moss K, Adib D, Schlechter B. A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors. SITC Annual Meeting 11(Suppl 1):738, 2023. e-Pub 2023.
105. Dumbrava EE, Chmielowski B, Shepard D, Vena D, Rasco D, Sharma M, Hamilton E, Papadopoulos K, Wang J, Ophir E, Ferre P, Barbiro I, Cojocaru G, Adewoye A, Patel M. The combination of COM701 + nivolumab demonstrates preliminary antitumor activity in patients with metastatic breast cancer. SITC Annual Meeting 11(Suppl 1):640, 2023. e-Pub 2023.
106. Gaillard S, Sharma M, Vaena D, Yeku O, Rasco D, Dumbrava EE, Papadopoulos K, Patnaik A, Sullivan R, Izar B, Ferre P, Ophir E, Barbio I, Cojocaru G, Adewoye A, Moroney J. Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer. SITC Annual Meeting, 2023. e-Pub 2023.
107. Giordano A, Dumbrava EE, Parikh A, Kenkel J, Cai D, Demady D, Xu L, Alonso M, Ackerman S, Perez E, Wilks S. A Phase 1/2 study of BDC-3042, a novel Dectin-2 agonistic antibody, in patients with advanced cancers. SITC Annual Meeting 11(Suppl 1):720, 2023. e-Pub 2023.
108. Dumbrava EE, Chen CT, Cote GM, Hanna GJ, Stinchcombe TE, Sumrall B, Wise-Draper T, Kanaan M, Duffy S, Sumey C, Cobb P, Shah N, Zhang B, Ku N, Doebele RC, Gounder M. A phase 2 basket study of the oral MDM2 inhibitor milademetan for MDM2-amplified advanced solid tumors (MANTRA-2). AACR-NCI-EORTC International Conference on Moledular Targets and Cancer Therapeutics 22(12 Suppl):B034, 2023. e-Pub 2023.
109. Michel L, Jimeno A, Sukrai A, Beck T, Chiu J, Ahern E, Hilton J, Hollebecque A, Zanetta S, Patel J, Mekan S, Wu T, Dumbrava EE. Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase 2 TROPiCS-03 basket trial. ESMO Congress 34(Suppl 2):S558, 2023. e-Pub 2023.
110. McKean M, Dumbrava EE, Hamid O, Merriam P, Call J, Feely W, Green A, Vaishampayan U, Moore K, Weroha S, Krishnan S, George A. Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors. ESMO Congress, 2023. e-Pub 2023.
111. Li B, Lee KW, Pegram M, Sharma M, Lee J, Spira A, Kang YK, Moore K, Rasco D, Hanna G, Weinberg B, Yu T, Alonso M, Ptacek J, Yin M, Tapia C, Xu L, Perez E, Dumbrava EE. Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors. ESMO Congress 34(Suppl 2):S462-S463, 2023. e-Pub 2023.
112. Dumbrava EE, Calvo E, Garralda E, Ryu MH, D-Y O, L-Y B, Chung W, Rojas Laimito KI, Yildirim O, Masciari S, Kang K, Buday B, Rharbaoui F, Abbadessa G, Moreno Garcia V. A Phase 1/1b Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study of a HER2-targeted T Cell Engager (SAR443216) in Patients with Relapsed/Refractory HER2-expressing Solid Tumors. ESMO Congress 34(Suppl 2):S647, 2023. e-Pub 2023.
113. Yap TA, Piha-Paul SA, Karp D, Dumbrava EE, Hong DS, Fu S, Subbiah V, Tsimberidou AM, Rodon J, Rhudy J, Valladolid C, Yuan Y, Jana B, Spiliopoulou P, Randall L, Poklepovic A, Sehgal K, Shapiro GI, Said R, Meric-Bernstam F. NCI10221: Phase II Multicenter Biomarker Driven Combination Trial of Copanlisib and Nivolumab in Patients with Molecularly-selected Advanced Solid Tumors (BaCoN). ESMO Congress 34(Suppl 2):S487-S488, 2023. e-Pub 2023.
114. Hong JY, Ryoo BY, Chenard-Poirier M, Almhanna K, Lim DWT, Samol J, Abbadessa G, Meng R, Masciari S, Kefsi A, Zhang Y, Guillemin-Paveau H, Pasquier B, Lepine L, Dumbrava EE. Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results. ESMO Congress 34(Suppl 2):S634, 2023. e-Pub 2023.
115. Olson D, Dumbrava EE, George M, Saibil S, Giordano A, Gavrilliuc M, Pieke B, Lichtenstein E, Apostolopoulou M, Moss K, Kirkwood D, Dang S, Adib D, Schlechter BL. A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. ESMO Congress 34(Suppl 2):S860, 2023. e-Pub 2023.
116. Schlechter B, Dumbrava EE, Saibil S, Gutierez M, Iqbal S, Sohal D, Apostolopoulou M, Moss K, Adib D, Olson D. A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors. AACR-NCI-EORTC International Conference on Moledular Targets and Cancer Therapeutics, 2023. e-Pub 2023.
117. DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann P, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. Co-clinical trial of novel bispecific anti-HER2 antibody Zanidatamab in Patient-Derived Xenografts. AACR-NCI-EORTC International Conference on Moledular Targets and Cancer Therapeutics 22(12 Suppl):B126, 2023. e-Pub 2023.
118. Schlecter B, Dumbrava EE, George M, Saibil S, Butler M, Antonio G, Pieke B, Gavriliuc M, Lichtenstein E, Geisberger J, Apostolopoulou M, Moss K, Kirkwood D, Dang S, Adib D, Olson D. A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 22(12 Suppl):B035, 2023. e-Pub 2023.
119. George GC, Piha-Paul SA, Fu S, Dumbrava EE, Subbiah V, Tsimberidou A, Blumenschein G, Pant S, Appleton G, Noor L, Rodon Ahnert J, Yap T, Meric-Bernstam F, Cleeland C, Mendoza T, Hong DS. Patient-reported baseline symptomatic adverse events in early-phase trials of combination treatments with immune checkpoint blockade, and their association with concurrent global health status, health utilities and clinical factors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 22(12 Suppl):C067, 2023. e-Pub 2023.
120. Schram AM, Shapiro GI, Johnson ML, Tolcher AW, Thompson JA, El-Khoueiry AB, Vandross AL, Kummar S, Parikh AR, Shepard DR, Garczarek U, LeDuke K, Sheehan L, Fellous M, Alland L, Dumbrava EE. Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation. AACR-NCI-EORTC International Conference on Moledular Targets and Cancer Therapeutics 22(12 Suppl):LB_A25, 2023. e-Pub 2023.
121. George GC, Piha-Paul SA, Fu S, Rodon Ahnert J, Yap TA, Subbiah V, Dumbrava EE, Tsimberidou A, Pant S, Appleton G, Noor L, Meric-Bernstam F, Cleeland CS, Mendoza TR, Hong DS. Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies. ASCO Annual Meeting 41(16 Suppl):12117, 2023. e-Pub 2023.
122. Santin A, Corr B, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Dumbrava EE. TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC). ASCO Annual Meeting 41(16 Suppl):5610, 2023. e-Pub 2023.
123. Li B, Pegram M, K-W L, Sharma M, Lee J, Spira A, Hanna G, U-K K, Rasco D, Moore K, Weinberg B, Alonso M, Ptacek J, Yin M, Tapia C, Xu L, Perez E, Dumbrava EE. A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors. ASCO Annual Meeting 41(16 Suppl):2538, 2023. e-Pub 2023.
124. Johnson B, Willis J, Williams C, Wang X, Smith G, You YN, Dumbrava EE, Fu S, Karp D, Naing A, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Yap T, Overman M, Pant S, Hong D, Kopetz S, Meric-Bernstam F, Subbiah V. Molecular landscape and survival outcomes on early phase clinical trials in sporadic young onset colorectal cancer. ASCO Annual Meeting 41(16 Suppl):3600, 2023. e-Pub 2023.
125. Nardo M, Gouda M, Ahmed J, Noia Barreto CM, Nelson B, Araujo D, Blumenschein G, Tsimberidou A, Piha-Paul S, Dumbrava EE, Hong D. Predictors of survival outcomes in patients (pts) with advanced solid tumors treated with cellular therapies in early clinical trials. ASCO Annual Meeting 41(16 Suppl):e14532, 2023. e-Pub 2023.
126. Rasco D, Vaena D, Fleming G, Dumbrava EE, Yeku O, Sharma M, Papadopoulos K, Sullivan R, Gaillard S, Adewoye A, Moroney J. Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer. ASCO Annual Meeting 41(16 Suppl):5610, 2023. e-Pub 2023.
127. Dumbrava EE, Cecchini M, Zugazagoitia J, Lopez J, Jäger D, Oliva M, Ochsenreither S, Gambardella V, Chung K, Longo F, Razak AA, Wermke M, Evans TRJ, Cook N, Chenard-Poirier M, Pencheva R, Schaer D, Wagener T, Wagner A, Papadopoulos K. Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors. ASCO Annual Meeting 41(Suppl 16):2502, 2023. e-Pub 2023.
128. Davidson T, Le H, Campbell E, Ozenne C, Dumbrava EE, Fu S, Hong D, Karp D, Naing A, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Yap T, Meric-Bernstam F, Subbiah V. Clinical trial deserts: US urban vs rural patient enrollment among patients with advanced cancer in phase 1 clinical trials at a major cancer center. ASCO Annual Meeting 41(16 Suppl):e18594, 2023. e-Pub 2023.
129. Cabanas EG, Fontana E, Oberoi HK, Uboha NV, Dumbrava EE, Calvo E, Curigliano G, Davar D, Keenan BK, Lam VK, manda S, Mehta A, Monchom A, Moskowitz A, Paluri R, Ribrag V, Richards D, Siu L, Swiecicki P, Wise-Draper T, Zain J, Forero-Torres A, Xu P, Ansel S. Phase 1 dose-escalation study of SGN-TGT monotherapy in patients with advanced malignancies. AACR Annual Meeting 83(8 Suppl):CT265, 2023. e-Pub 2023.
130. Dumbrava EE, Olson D, Saibil S, Pieke B, George MA, Bouvier R, Gavriliuc M, Gruber K, Moss K, Ternus N, Apostolopoulou M, Adib D, Schlechter BL. A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. AACR Annual Meeting 83(8 Suppl):CT234, 2023. e-Pub 2023.
131. Papadopoulos K, Cecchini M, Lopez JS, Jäger D, Chung KY, Platten M, Prinz F, Ishii Y, Schaer D, Gutcher I, Leder G, Pencheva R, Wagener T, Scheerans C, Zieschang C, Wagner A, Stamatelos S, Dumbrava EE. Preliminary analysis of pharmacokinetic (PK) and target engagement biomarkers from a first in human phase 1 study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964. AACR Annual Meeting 83(8 Suppl):CT276, 2023. e-Pub 2023.
132. Holla V, Ronaghy A, Yang RK, Patel KP, Routbort MJ, Overman MJ, Dumbrava EE, Shaw KR, Karp DD, Meric-Bernstam F. Genomic alterations in DNA mismatch repair (dMMR). AACR Annual Meeting 83(7 Suppl):2128, 2023. e-Pub 2023.
133. Uzunparmak B, Haymaker C, Raso G, Zhu C, Masciari S, Wang L, Kirby B, Lin H, Gorur A, A-M C, Kennon A, Ding Q, Palmieri A, Urschel GE, Yuan Y, Feng G, Rizvi Y, Hussain A, Subbiah V, Yap TA, Rodon-Ahnert J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. AACR Annual Meeting 83(7 Suppl):961, 2023. e-Pub 2023.
134. Ngoi NY, Lin HY, Dumbrava EE, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Dynamic changes in monocyte and reticulocyte counts predict mechanism-based anemia development and recovery during ATR inhibitor treatment in phase I/II trials. AACR Annual Meeting 83(7 Suppl):6181, 2023. e-Pub 2023.
135. Nelson BE, Janku F, Fu S, Dumbrava EE, Hong DS, Karp D, Naing A, Rodon J, Tsimberidou A, Amaria RN, Conley A, Damodaran S, Raghav KPS, Kreider BL, Tung D, Varterasian M, Khazaie K, Piha-Paul S. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. AACR Annual Meeting 83(8 Suppl):CT107, 2023. e-Pub 2023.
136. Schlechter BL, Olson D, Saibil S, George MA, Gruber K, Bouvier R, Pieke B, Geisburger J, Moss KM, Ternus N, Adib DR, Dumbrava EE. A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors. ASCO Gastrointestinal Cancers Symposium 41(4 Suppl):TPS816, 2023. e-Pub 2023.
137. Stein M, Teply B, Gergis U, Strickland D, Senesac J, Bayle H, Chatwal M, Bilen M, Stadler W, Dumbrava EE. Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX-601) in patients with metastatic castration-resistant prostate cancer (mCRPC). ASCO Genitourinary Cancers Symposium 41(Suppl 6):140, 2023. e-Pub 2023.
138. Oh D, Henry J, Baranda JC, Dumbrava EE, Cohen E, Eskew JD, Belani R, McCaigue J, Namini H, Martin C, Murphy A, Ostertag E, Coronella J, Shedlock D, Rodriguez Rivera II. Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors. ESMO Immuno-Oncology Congress 16(Suppl 1):100151, 2022. e-Pub 2022.
139. Moroney J, Yeku O, Fleming G, Emens LA, Vaena D, Dumbrava EE, Rasco D, Sharma MR, Papadopoulos K, Patnaik A, Sullivan RJ, Adeqoye HH, Ophir E, Cojocaru G, Ferre PJ, Izar B, Gaillard S. Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant OVCA. ESMO Immuno-Oncology Congress 16(Suppl 1):100104, 2022. e-Pub 2022.
140. Schlechter BL, Olson D, Saibil S, George M, Bouvier R, McKinley J, Pieke B, Geisburger J, Ternus NJ, Moss K, Adib D, Dumbrava EE. A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors. SITC Annual Meeting 10(Suppl 2):A791, 2022. e-Pub 2022.
141. Rasco D, Dumbrava EE, Sharma MR, Shepard D, Vaena D, Fleming G, Chmielowski B, Hamilton EP, Sullivan RJ, Papadopoulos KP, Patnaik A, fOphir E, Cojocaro G, Bohac C, Adewoye AH, Patel MR, Overman MJ. COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases. SITC Annual Meeting 10(Suppl 2):659, 2022. e-Pub 2022.
142. Henry J, Oh D, Eskew JD, Baranda J, Rodriguez Rivera II, Dumbrava EE, Cohen E, Belani R, McCaigue J, Shedlock DJ, Coronella J, Martin CE, Namini H, Murphy A, Ostertag EM. Phase 1 study of P-MUC1C-ALLO1 allogeneic CAR-T cells in patients with epithelial-derived cancers. SITC Annual Meeting 10(Suppl 2):A760, 2022. e-Pub 2022.
143. Yap TA, Ngoi N, Dumbrava EE, Karp DD, Rodon Ahnert J, Fu S, Hong DS, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Dufner D, Rhudy J, Gore S, Ivy SP, Yuan Y, Westin SN, Mills GB, Meric-Bernstam F. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly(ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 174(Suppl 1):S7, 2022. e-Pub 2022.
144. Ngoi N, Pilie PG, Piha-Paul SA, Dumbrava EE, Fu S, Hong DS, Karp DD, Naing A, Pant S, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Salguero C, Brown CV, Hoadley WE, Johnson A, Yuan Y, Westin SN, Meric-Bernstam F, Yap TA. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: Phase 1/2 Study of the ATR inhibitor (ATRi) berzosertib and PD-L1 inhibitor avelumab in patients (pts) with advanced solid tumors with DDR molecular alterations. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 174(Suppl 1):19, 2022. e-Pub 2022.
145. Ngoi NY, Lin H, Dumbrava EE, Fu S, Karp D, Naing A, Pant S, Rodon J, Piha-Paul SA, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials. ESMO Congress 33(S7):S761-S762, 2022. e-Pub 2022.
146. Hamid O, Sato T, Davar D, Callahan M, Thistlethwaite F, Aljumaily R, Johnson M, H-T A, Dumbrava EE, Izar B, Chen HA, Marshall S, Yuan Y, Deo M, Stanhope S, Collins L, Mundy R, Abdullah S, Lopez J. Results from Phase 1 dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors. ESMO Congress 33(S7):S875, 2022. e-Pub 2022.
147. Schlechter BL, Dumbrava EE, Olson D, Saibil S, Pieke B, Bouvier R, Moss K, Turnus N, Bader A, Adib D. A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors. ESMO Congress 33(S7):S896, 2022. e-Pub 2022.
148. Ngoi N, Lin HY, Dumbrava EE, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Campbell E, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Baseline predictors of hematological toxicity in patients with advanced cancer treated with ATR inhibitors in phase I/II clinical trials. ASCO Annual Meeting 40(Suppl 16):3111, 2022. e-Pub 2022.
149. Dumbrava EE, Burton EM, Subudhi SK, Milton DR, Aparicio A, Yap TA, Naing A, Gettys Corn P, Pilie PG, Zurita AJ, Wang J, Navroze Amaria R, McQuade JL, Glitza IC, Lazar AJ, Meric-Bernstam F, Logothetis C, Davies MA, Hwu P, Tawbi HA. Phase I/II study of the selective PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and PTEN loss. ASCO Annual Meeting 40(Suppl 16):5052, 2022. e-Pub 2022.
150. Dumbrava EE, Johnson ML, Tolcher AW, Shapiro G, Thompson JA, El-Khoueiry AB, Vandross AL, Kummar S, Parikh AR, Munster PN, Daly E, De Leon L, Khaddar M, LeDuke K, Robell K, Sheehan LI, St Louis M, Wiebesiek A, Alland L, Schram AM. First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation. ASCO Annual Meeting 40(Suppl 16):3003, 2022. e-Pub 2022.
151. Coleman N, DiPeri TP, Nguyen D, Naing A, Piha-Paul SA, Tsimberidou AM, Zheng X, Johnson A, Wang W, Shaw KR, Dumbrava EE, Fu S, Rodon J, Rodon Ahnert J, Hong DS, Subbiah V, Yap TA, Luthra R, Patel KP, Meric-Bernstam F. Repeat large panel genomic sequencing identifies actionable alterations and characterizes the genomic landscape in patients with metastatic solid tumors. ASCO Annual Meeting 40(Suppl 16):3076, 2022. e-Pub 2022.
152. Nelson BE, Andersen C, Yuan Y, Hong DS, Naing A, Karp DD, Yap TA, Rodon Ahnert J, Campbell E, Tsimberidou AM, Dumbrava EE, Fu S, Piha-Paul SA, Pant S, Blumenschein GR, Altan M, Tawbi HA, Tannir NM, Meric-Bernstam F, Subbiah V. Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers. ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
153. McKean M, Dumbrava EE, Hamid O, Merriam P, Mettu NB, Call JA, Kapoun AM, Lucas J, Seetharam M, Vaishampayan UN, Veroha SJ, Krishnan S, George AJ. Safety and efficacy of etigilimab in combination with nivolumab in select recurrent/advanced solid tumors. ASCO Annual Meeting 40(suppl 16):2651, 2022. e-Pub 2022.
154. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul SA, More JA, Yilmaz B, Karp DD, Dumbrava EE, Tsimberidou AM, Hong DS, Rodon Ahnert J, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer. ASCO Annual Meeting 40(suppl 16):3108, 2022. e-Pub 2022.
155. Piha-Paul SA, Xu B, Singh Raghav KP, Meric-Bernstam F, Janku F, Dumbrava EE, Fu S, Karp DD, Rodon Ahnert J, Conley AP, Mott F, Ajani JA, Hong DS, Fan Y, Peng P, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. ASCO Annual Meeting 40(suppl 16):3013, 2022. e-Pub 2022.
156. Schlechter B, Olson D, George M, Saibil S, Giordano A, Bouvier R, Gavriliuc M, Pieke B, Gruber K, Lichtenstein E, Apostolopoulou M, Moss K, Ternus N, Adib D, Dumbrava EE. A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. ASCO Annual Meeting 41(15 Suppl):2519, 2022. e-Pub 2022.
157. Alhalabi O, Tannir NM, Momin HA, Yilmaz B, Stephen B, Ejezie CL, Moyers JT, Gurses SA, How J, Fu S, Rodon Ahnert J, Hong DS, Piha-Paul SA, Subbiah V, Dumbrava EE, Karp DD, Janku F, Meric-Bernstam F, Naing A. Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience. ASCO Annual Meeting 40(Suppl 16):4551, 2022. e-Pub 2022.
158. Dumbrava EE, Hanna GJ, Cote GM, Stinchombe T, Johnson ML, Chen C, Devarakonda S, Shah N, Xu F, Doebele RC, Gounder MM. A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2). ASCO Annual Meeting 40(Suppl 16):TPS3165, 2022. e-Pub 2022.
159. Dumbrava EE, Olson D, Schlechter BL, Saibil S, Rill D, Bader A, Adib D, Bishop M. A phase I/II trial investigating safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors (TACTIC-2). AACR Annual Meeting 82(12 Suppl):CT247, 2022. e-Pub 2022.
160. Zhao M, DiPeri TP, Raso G, Rizvi YQ, Zheng X, Evans K, Akcakanat A, Yang F, Tripathy D, Dumbrava EE, Damodaran S, Meric-Bernstam F. Epigenetically upregulating TROP2 enhances therapeutic efficacy of TROP2 ADC sacitizumab govitecan. AACR Annual Meeting 82(12 Suppl):1791, 2022. e-Pub 2022.
161. DiPeri TD, Kong K, Karp DD, Ajani JA, Pant S, Piha-Paul SA, Dumbrava EE, Meric-Bernstam F. Discordance of HER2 expression and/or amplification on repeat testing. AACR Annual Meeting 82(12 Suppl):1588, 2022. e-Pub 2022.
162. Dumbrava EE, Hanna GJ, Cote GM, Stinchcombe TE, Johnson ML, Chen CT, Devarakonda SHK, Shah N, Xu F, Doebele RC, Gounder MM. A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2). AACR Annual Meeting 82(12 Suppl):CT123, 2022. e-Pub 2022.
163. Sharma MR, Carvajal RD, Hanna GJ, Kang Y, Lee J, Lee K, Li BT, More KN, Pegram M, Rasco D, Spira A, Wang D, Weinberg BA, Alonso M, Fang L, Husain A, Kowanetz M, Perez EA, Dumbrava EE. Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. ESMO Immuno-Oncology Congress 32(Suppl 7):S1453-S1454, 2021. e-Pub 2021.
164. Dumbrava EE, Sharma MR, Carvajal RD, Catenacci D, Emens LA, Gadgeel SM, Hanna GJ, Juric D, Y-K K, Lee J, K-W L, Li BT, Moore K, Pegram MD, Pohlmann PR, Rasco D, Spria A, Tan AR, Ackerman SE, LeBlanc H, Dornan D, Kowanetz M, Alonso MN, Perez EA. Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. San Antonio Breast Cancer Symposium 81(4 Suppl):OT-03-02, 2021. e-Pub 2021.
165. Davar D, Ribrag V, Sarkozy C, Garralda E, Kumar Oberoi H, Mehta A, Curigliano G, Belli C, Zain J, Herrera A, Sanborn R, Dumbrava E Forero-Torres A, Ansell S. Phase 1 Study Of SEA-TGT, A Human, Nonfucosylated Anti-Tigit Monoclonal Antibody With Enhanced Immune-Effector Function, In Patients With Advanced Malignancies (Sgntgt-001, Trial In Progress). SITC Annual Meeting 9(suppl 2):474, 2021. e-Pub 2021.
166. Dumbrava EE, Sharma M, Fleming G, Papadopoulos K, Sullivan R, Vaena D, Patnaik A, ElNaggar A, Adewoye A, Smith R, Ferré P, Barbiro I, Lim E, Rasco D. COM701 in combination with BMS-986207 (Anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839). SITC Annual Meeting 9(Suppl 2):478, 2021. e-Pub 2021.
167. Dumbrava EE, Rasco D, Patnaik A, Vaena D, Papadopoulos K, ElNaggar A, Adewoye A, Smith R, Ferré P, Vaknin I, Devarakonda S, Sharma M. COM902 (Anti-Tigit Antibody) Monotherapy – Preliminary Evaluation Of Safety, Tolerability, Pharmacokinetics And Receptor Occupancy In Patients With Advanced Solid Tumors (NCT04354246). SITC Annual Meeting 9(Suppl 2):477, 2021. e-Pub 2021.
168. Moyers J, Nguyen D, Hong DS, Dumbrava EE, Fu S, Karp D, Naing A, Pant S, Janku F, Piha-Paul S, Rodon J, Subbiah V, Tsimberidou AM, Meric-Bernstam F, Yap TA. Adherence to the Food and Drug Administration (FDA) Guidance for the Co-Development of Two or More Investigational New Drugs in Phase 1/2 Cancer Trials. ESMO Congress 32(suppl 5):838, 2021. e-Pub 2021.
169. Park H, Shapiro G, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Hickman D, Gallacher PD, Attar EC, Awad MM, Das S, Dumbrava EE. Phase 1/2 study of Eprenetapopt (APR-246) in Combination with Pembrolizumab in Patients with Solid Tumor Malignancies. ESMO Congress 32(Suppl 5):S586, 2021. e-Pub 2021.
170. Burton E, Dumbrava EE, Peng W, Milton D, Amaria R, Mcquade J, Glitza IC, Hong D, Patel S, Rodon J, Yap TA, Naing A, Piha-Paul SA, Balmes G, Lazar A, Meric-Bernstam F, Hwu P, Davies MA, Tawbi HA. Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors. ESMO Congress 32(suppl 5):S899, 2021. e-Pub 2021.
171. Yap TA, Dumbrava EE, Rodon Ahnert J, Hong DS, Pant S, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Fu S, Janku F, Montez S, Ahmad-Taha MT, Guerrero D, Nazarenko NN, Moore Y, Soth M, Kovacs J, Heffernan TP, Jones P. First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors. ASCO Annual Meeting 39(suppl 15):3001, 2021. e-Pub 2021.
172. Robert F, Dumbrava EE, Xing Y, Mills E, Freddo JL, Theuer CP, Adams BJ, Lawrence J, Trigeiro AA, Xu C, Meng Y, Lee L, Zhao Y, Wang J, Shen HJ, Gordon MS. Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer. ASCO Annual Meeting 39(supple 15):2511, 2021. e-Pub 2021.
173. Govindan R, Townsend AR, Miller KD, Mehmi I, Kuboki Y, Dumbrava EE, Hamilton EP, Vuu I, Rasmussen E, Mileshkin LR, Genta S, Iwata H, Adams S, Fujii H, Chawla SP. Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors. ASCO Annual Meeting 39(suppl 15):TPS5600, 2021. e-Pub 2021.
174. Vaena DA, Fleming GF, Chmielowski B, Sharma M, Hamilton EP, Sullivan RJ, Shepard DR, Papadopoulos KP, Patnaik A, ElNaggar A, Adewoye AH, Smith R, Lim EA, Dumbrava EE, Rasco DW. COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716). ASCO Annual Meeting 39(suppl 15):2504, 2021. e-Pub 2021.
175. Sharma M, Carvajal RD, Hanna GJ, Li BT, Moore KN, Pegram MD, Rasco DW, Spira AI, Alonso M, Fang L, Husain A, Perez EA, Dumbrava EE. Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. ASCO Annual Meeting 39(suppl 15):2549, 2021. e-Pub 2021.
176. Piha-Paul SA, Xu B, Janku F, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Javle MM, Fan Y, Peng P, Levin WJ, Ngo B, Wang H, Sun C, Ru QC, Wu F. Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. ASCO Annual Meeting 39(suppl 15):3090, 2021. e-Pub 2021.
177. Abo-Zahrah R, Karp DD, Adat A, Yap TA, Fu S, Rodon Ahnert J, Piha-Paul SA, Tsimberidou AM, Naing A, Subbiah V, Dumbrava EE, Overman MJ, Patel SP, Amaria RN, Westin SN, Meric-Bernstam F, Janku F. Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progression in lymphatic nodes. ASCO Annual Meeting 39(suppl 5):3138, 2021. e-Pub 2021.
178. Coleman N, Naing A, Zhang S, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EE, Fu S, Hong DS, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. ASCO Annual Meeting 39(suppl 15):3017, 2021. e-Pub 2021.
179. Park H, Shapiro G, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Hickman D, Gallacher PD, Attar EC, Awad MM, Das S, Dumbrava EE. Phase 1/2 study of Eprenetapopt (APR-246) in Combination with Pembrolizumab in Patients with Solid Tumor Malignancies. ASCO Annual Meeting 32(suppl 5):S586, 2021. e-Pub 2021.
180. Dumbrava EE, Shapiro G, Bendell JC, Yap TA, Jeselsohn R, Lepley DM, Hurley S, Lin KK, Liao M, Habeck J, Enke A, Hamilton EP. Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors. ASCO Annual Meeting 39(suppl 15):3102, 2021. e-Pub 2021.
181. Dumbrava EE, Dougan ML, Gupta S, Cappelli L, Katsumoto TR, Rahma OE, Painter J, Wang Y, Suarez-Almazor ME, Reid P, Wesley SF, Hafler DA, Bingham CO, Warner BM, Chung L, Ott PA, Kluger HM, Khosroshahi A, Tawbi HA, Sharon E. A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). ASCO Annual Meeting 39(15 suppl):TPS2676, 2021. e-Pub 2021.
182. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal R, George TJ, Yuan Y, Yamamura Y, Westin S, Xing Y, Ileana Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Rodon J, Takebe N, Kunos C, Lu K, Keyomarsi K, Meric-Bernstam F. Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification. AACR Annual Meeting 81(suppl 13):974, 2021. e-Pub 2021.
183. Sharma MR, Carvajal RD, Catenacci D, Emens LA, Hanna GJ, Juric D, Y-K K, Lee J, K-W L, Li BT, Moore K, Pegram MD, Pohlmann PR, Rasco D, Spira A, Heeke AL, Wang D, Garbo L, Manda S, Sachdev J, Ackerman SE, LeBlanc H, Dornan D, Kowaneta M, Alonso MN, Husain A, Perez EA, Dumbrava EE. Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors. AACR Annual Meeting 81(suppl 13):CT218, 2021. e-Pub 2021.
184. Dumbrava EE, Sharma MR, Carvajal RD, Catenacci D, Emens LA, Gadgeel SM, Hanna GJ, Dejan Juric D, Kang YK, Lee J, Lee KW, Li BT, Moore K, Pegram MD, Pohlmann PR, Rasco D, Spira A, Tan AR, Ackerman SE, LeBlanc H, Dornan D, Kowanetz M, Alonso MN, Perez EA. Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. San Antonio Breast Cancer Symposium 81(suppl 4):OT-03-02, 2020. e-Pub 2020.
185. Hong DS, Butler MO, Russell Pachynski R, Sullivan RJ, Kebriaei P, Boross-Harmer S, Frigault MJ, Dumbrava EE, Sauer A, Brophy F, Navenot JM, Fayngerts S, Bai J, Norry E, Fracasso PG. Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors. SITC Annual Meeting 8(Suppl 3):285, 2020. e-Pub 2020.
186. Sharma MR, Dumbrava EE, Carvajal RD, Catenacci DV, Emens LA, Hanna GJ, Juric D, Kang YK, Lee J, Lee KW, Li BT, Moore KN, Pegram MD, Pohlmann PR, Rasco D, Spira AI, Tan A, Wang D, Ackerman SE, LeBlanc HN, Dornan D, Kowanetz M, Alonso MN, Perez EA. Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. SITC Annual Meeting 8(Suppl 3):401, 2020. e-Pub 2020.
187. Fu S, Hong D, Fogelman D, Shaikh F, Dupont-Roettger D, Bisdas S, Ileana Dumbrava EE, Piha-Paul S, Liu S, Dugourd D, Yamamura Y. A phase Ib study on a TRPV6-inhibitor, SORC13 in patients with advanced solid tumours. ESMO Congress 31(Supplement 4):S462-S504, 2020. e-Pub 2020.
188. Yap TA, Hamilton EP, Bauer TM, Ileana Dumbrava EE, Jeselsohn R, Enke A, Hurley S, Lin KK, Wride K, Giordano H, Shapiro G. Rucaparib + sacituzumab govitecan (SG): Initial data from the phase Ib/II SEASTAR study (NCT03992131). ESMO Congress 31(Supplement 4):S462-S504, 2020. e-Pub 2020.
189. Subbiah IM, Buzdar A, Dumbrava EE, Fu S, Janku F, Karp DD, Naing A, Pant S, Rodon J, Tsimberidou AM, Yap TA, Subbiah V, Meric-Bernstam F, Hong DS. Investigating the disparate enrollment of older adults on phase I clinical trials: evolving participation patterns of patients 65 years and older w advanced cancer on phase I trials. ASCO Annual Meeting 38(15):12044, 2020. e-Pub 2020.
190. Pilie PG, Gheeya JS, Kyewalabye K, Goswamy RV, Wani KM, Le H, Campbell E, Sanchez NS, Yang D, Garmezy B, Dumbrava EE, Rodon Ahnert J, Heffernan T, Holla V, Shaw KR, Meric-Bernstam F, Lazar AJ, Wang W, Yap TA. Identifying functional loss of ATM gene in patients with advanced cancer. ASCO Annual Meeting 38(suppl 15):3629, 2020. e-Pub 2020.
191. Dumbrava EE, Suarez-Almazor ME, Painter J, Johanns T, Dougan ML, Cappelli L, Bingham CO, Wang Y, Gupta S, Warner BM, Rahma OE, Naidoo J, Ott PA, Hafler DA, Kluger HM, Khosroshahi A, Katsumoto TR, Kummar S, Sharon E, Tawbi H. A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). ASCO Annual Meeting 38(suppl 15):TPS3158, 2020. e-Pub 2020.
192. Piha-Paul SA, Dumbrava EE, Janku F, Karp DD, Meric-Bernstam F, Rodon J, Ngo B, Peng P, Wu F. Phase I study of TT-00420, a multiple kinase inhibitor, in patients with triple negative breast cancers and other advanced solid tumors. ASCO Annual Meeting 80(16):3011, 2020. e-Pub 2020.
193. Dumbrava E, Suarez-Almazor M, Painter J, Johanns TM, Dougan ML, Cappelli L, Wang Y, Bingham C, Gupta S, Warner BM, Rahma O, Naidoo J, Ott PA, Hafler DA, Kluger H, Khosroshahi A, Naqash R, Chung L, Katsumoto TR, Kummar S, Tawbi H, Sharon E. A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). AACR Annual Meeting 80(16):CT249, 2020. e-Pub 2020.
194. Sullivan R, Rasco D, Lim E, Sharma M, Shepard D, Patnaik A, Hamilton E, Fleming G, Papadopoulos K, ElNaggar A, Adewoye AH, Chmielowski B, Dumbrava E, Vaena D. COM701 demonstrates preliminary antitumor activity as monotherapy and in combination with nivolumab in patients with advanced solid tumors. AACR Annual Meeting 80(16):CT031, 2020. e-Pub 2020.
195. Hegde A, Jayaprakash P, Sumner E, Nguyen D, Zain H, Piha-Paul SA, Karp D, Rodon J, Pant S, MBBS, Fu S, Dumbrava EE, Yap TA, PhD MD, Subbiah V, Bhosale P, Higgins JP, Williams ET, Wilson TF, Meric-Bernstam F, Curran MA, Hong DS. A Phase 1 Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. SITC Annual Meeting 7(Part 1), 2019. e-Pub 2019.
196. Dumbrava EE, Fleming GF, Hamilton EP, Sullivan RJ, Patnaik A, Papadopoulos KP, ElNaggar A, Hunter J, Olweny J, Adewoye AH, Chmielowski B, Shepard D, Sharma MR, Lim E, Vaena D, Rasco D. Phase 1 study of the safety, tolerability and preliminary anti-tumor activity of COM701 monotherapy in patients with advanced solid tumors. SITC Annual Meeting 7(Part 1), 2019. e-Pub 2019.
197. Dumbrava EE, Fleming G, Hamilton EP, Sullivan RJ, Patnaik A, Papadopoulos KP, ElNaggar A, Hunter J, Olweny J, Adewoye AH, Adewoye AH, Chmielowski B, Shepard D, Sharma MR, Lim E, Vaena D, Rasco D. Phase 1 study of COM701 monotherapy and in combination with nivolumab in patients with advanced solid tumors. SITC Annual Meeting 7(Part 1), 2019. e-Pub 2019.
198. Pairawan S, Evans K, Kopetz S, Akcakanat A, Zhao M, Tapia C, Busaidy N, Dumbrava EE, Meric-Bernstam F. The combination of MEK and MDM2 inhibitors demonstrates promising antitumor efficacy in MAPK altered patient-derived thyroid and colorectal cancer models. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 18(12 Suppl):C080, 2019. e-Pub 2019.
199. Coyne GO, Yap T, Moore N, Mittra A, Takebe N, Juwara L, Khan S, Dumbrava EE, Streicher H, Piekarz R, Sharon E, Meric-Bernstam F, Parchment R, Navas T, Fung K, Mitchell J, Fino K, Montez S, Doyle A, Rubinstein L, Doroshow J, Chen A. Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 18(12 Suppl):B105, 2019. e-Pub 2019.
200. Naing A, Meric-Bernstam F, Karp D, Rodon JA, Piha-Paul SA, Subbiah V, Hong DS, Pant S, Fu S, Janku F, Yap TA, Tsimberidou AM, Dumbrava EE, Colen RR, Hess KR, Campbell MT, Tu S, Jimenez C, Habra MA, Varadhachary GR. Pembrolizumab in Advanced Rare Cancers. ESMO Congress 30(suppl 5):v516-v517, 2019. e-Pub 2019.
201. Meric-Bernstam F, Somaiah N, DuBois SG, Dumbrava EE, Shapiro GI, Patel MR, Goel S, Bauer T, Pinchasik D, Annis A, Aivado M, Vukovic V, Saleh M. A phase IIa clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification. ESMO Congress 30(Suppl 5):v179-v180, 2019. e-Pub 2019.
202. Yap TA, Rodon Ahnert J, Piha-Paul SA, Fu S, Janku F, Karp DD, Naing A, Ileana Dumbrava EE, Pant S, Subbiah S, Tsimberidou AM, Hong DS, Rose KM, Xu Q, Vellano CP, Mahendra M, Jones P, Di Francesco ME, Marszalek JR, Meric-Bernstam F. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. ASCO Annual Meeting 37(15 suppl):3014, 2019. e-Pub 2019.
203. Naing A, Ileana Dumbrava E, Murthy R, Meric-Bernstam F, Fox A, Krige D, Carter J, Champion B, Cockle P, Koetz B, McElwaine-Johnn H. A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE). ASCO Annual Meeting 37(15 suppl):TPS2668, 2019. e-Pub 2019.
204. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EE, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Amir Habra M. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer, 2019. e-Pub 2019. PMID: 32188704.
205. Pairawan SS, Yuca E, Evans K, Annis A, Narasimhan N, Sutton D, Carvajal LA, J-G R, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Ileana Dumbrava E, Aivado M, Meric-Bernstam F. The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer models. San Antonio Breast Cancer Symposium 79(Suppl 4):P6-20-11, 2018. e-Pub 2018.
206. Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Tapia C, Ileana Dumbrava E, Janku F, Meric-Bernstam F. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. San Antonio Breast Cancer Symposium 79(4 Suppl):P6-21-04, 2018. e-Pub 2018.
207. Ileana Dumbrava E, Huang HJ, Stuckett A, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp D, Fu S, Naing A, Tsimberidou AM, Moulder S, Koenig K, Barcenas CH, Kee B, Fogelman D, Kopetz S, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma cell-free DNA predict survival and treatment outcomes in patients with advanced cancers. AACR Special Conference on Targeting PI3K/mTOR Signaling 18(10 Suppl):PR10, 2018. e-Pub 2018.
208. Ileana Dumbrava EE, Huang HJ, Stuckett A, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder S, Koeing K, Barcenas CH, Kee B, Fogelman D, Kopetz S, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma cell-free DNA predict survival and treatment outcomes in patients with advanced cancers. AACR Special Conference on Targeting PI3K/mTOR Signaling, 2018. e-Pub 2018.
209. Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Ileana Dumbrava E, Janku F, Meric-Bernstam F. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. AACR Special Conference on Targeting PI3K/mTOR Signaling 18(10 Suppl):B07, 2018. e-Pub 2018.
210. Ileana Dumbrava E, Balaji K, Raghav K, Javle M, Blum-Murphy M, Sajan B, Kopetz S, Broaddus R, Routbort M, Pant S, Tsimberidou A, Subbiah V, Hong D, Rodon J, Shaw K, Piha-Paul S, Meric-Bernstam F. Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 17(1 Suppl):#A167, 2017. e-Pub 2017.
211. Ileana Dumbrava E, Brusco L, Daniels MS, Wathoo C, Shaw K, Lu K, Zheng X, Strong LC, Litton J, Arun B, Eterovic A, Piha-Paul S, Subbiah V, Hong DS, Woodman S, Mendelsohn J, Yap T, Mills CB, Chen K, Meric-Bernstam F. Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors. ASCO Annual Meeting 35(15 Suppl):#11567, 2017. e-Pub 2017.
212. Ileana Dumbrava EE, Brusco L, Daniels MS, Wathoo C, Shaw K, Lu K, Zheng X, Strong LC, Litton J, Arun B, Eterovic A, Routbort M, Piha-Paul S, Subbiah V, Hong DS, Kopetz S, Mendelsohn J, Yap T, Mills CB, Chen K, Meric-Bernstam F. Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors. ASCO Annual Meeting 35(15 Suppl):#1524, 2017. e-Pub 2017.
213. Shien K, Ruder D, Ileana E, Papadimitrakopoulou VA Frampton GM, Behrens C, Kalhor N, Lee JJ, Tang X, Herbst RS, Wistuba II, Izzo JG. Detection of a novel ALK fusion variant in lung adenocarcinoma using a comprehensive genomic analysis 76(suppl 14):pp. 1144, 2016. e-Pub 2016.
214. Ileana E, Jovelet C, Le Deley MC, Massard C, Motté N, Hollebecque A, Boichard A, Ferté C, Postel-Vinay S, Rosellini S, Ngo-Camus M, De Baere T, Vielh P, Richon C, Laporte M, Gouissem S, Loriot Y, Bahleda R, Gazzah A, Varga A, Vassal G, Eggermont A, André F, Soria JC, Lacroix L. Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial. AACR Annual Meeting 75(15 Suppl):2401, 2015. e-Pub 2015.
215. Ileana E, Antoun S, Albiges L, Massard C, Di Palma M, Escudier B, Fizazi K, Loriot Y. Effects of abiraterone acetate and enzalutamide on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC). ASCO Annual Meeting 31(Suppl 15):5088, 2013. e-Pub 2013.
216. Bianchini D, Loriot Y, Dumbrava EE, Sandhu S, Pezaro C, Albiges L, Attard G, Fizazi K, de Bono JS, Massard C. Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100: a multicentre study. ESMO Congress 23(Suppl 9):924P, 2012. e-Pub 2012.
217. Dumbrava EE, Loriot Y, Albiges L, Massard C, Blesius A, Palma MD, Escudier BJ, Blanchard P, Bossi A, Fizazi K. Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100. ASCO Annual Meeting 30(Suppl):4554, 2012. e-Pub 2012.
218. Ileana E, Maldonado F, Astoul P. Where did my central line go? The pinch-off syndrome 10(Suppl):#200, 2010. e-Pub 2010.
219. Dumbrava EE, Diaconu B, Tantau M, Laugier R. Efficacy of endoscopic treatment in chronic pancreatitis assessed by Izbicki Score. Meeting of the European Pancreatic Club 9:#P-103, 2009. e-Pub 2009.

Book Chapters

1. Ileana-Dumbrava E. Targeting DNA Damage Response. Handbook of Targeted Cancer Therapy and Immunotherapy. In: Wolters Kluwer. 2nd, 2018.
2. Herold J, Ileana-Dumbrava E. PDGFR and targeting PDGFRA. In: Wolters Kluwer. 2nd, 2018.
3. Ileana-Dumbrava E. TIE receptors. In: Wolters Kluwer. 2nd, 2018.
4. Perkins A, Ileana-Dumbrava E. Targeting IGFR-1 and Insulin Receptor. In: Wolters Kluwer. 2nd, 2018.
5. Marcelo-Lewis K, Ileana-Dumbrava E. Management of Immune-Related Toxicities Handbook of Targeted Cancer Therapy. In: Wolters Kluwer. 2nd, 2018.
6. Perkins A, Ileana-Dumbrava E. Targeting TGFß/SMAD Pathway. In: Wolters Kluwer. 2nd, 2018.

Books (edited and written)

1. Ileana Dumbrava E. Section 3: Molecular Targets and Pathways Handbook of Targeted Cancer Therapy and Immunotherapy. Ed(s) 3rd Edition. Wolters Kluwer, 2022.
2. Ileana Dumbrava E. Section 2: Molecular Targets and Pathways Handbook of Targeted Cancer Therapy and Immunotherapy. Ed(s) 2nd Edition. Wolters Kluwer, 2018.

Web Publications

1. Heidi Ledford. Landmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future treatments- (Interview with Dr. Dumbrava), 2026.
2. Nuria W Negrao. MDM2 Inhibition Marches on Across Cancer Settings- (Interview with Dr. Dumbrava), 2023.
3. Amorosi D. Early data from CAR macrophage trial show cell therapy is safe, feasible for solid tumors- (Perspective from Dr. Dumbrava), 2021.
4. Devon Carter. Can immunotherapy treat cancer in patients with autoimmune diseases?- (Interview with Dr. Dumbrava), 2021.
5. Devon Carter. Monoclonal antibodies and cancer treatment: What to know? (Interview with Dr. Dumbrava), 2020.